[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 825
1. Patrocinio LG, Patrocinio TG, Pacheco LF, Patrocinio JA: Trismus as the first manifestation of cholangiocarcinoma. Med Oral Patol Oral Cir Bucal; 2008 Sep;13(9):E573-5
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trismus as the first manifestation of cholangiocarcinoma.
  • The initial presentation of a cholangiocarcinoma (CC) as trismus due to metastasis to the parotid gland is extremely rare and no previous reports have been found in the literature.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / complications. Cholangiocarcinoma / secondary. Parotid Neoplasms / complications. Parotid Neoplasms / secondary. Trismus / etiology
  • [MeSH-minor] Adult. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758402.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Shin HR, Oh JK, Lim MK, Shin A, Kong HJ, Jung KW, Won YJ, Park S, Park SJ, Hong ST: Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci; 2010 Jul;25(7):1011-6
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea.
  • In 2009, infection with the liver fluke Clonorchis sinensis (C. sinensis) was classified as "carcinogenic to humans" (Group 1) based on its involvement in the etiology of cholangiocarcinoma by the International Agency for Research on Cancer.
  • However, little is known about the descriptive epidemiology of cholangiocarcinoma in Korea.
  • Cholangiocarcinoma incidence rates are currently rising, even while primary liver cancer incidence rates are decreasing.
  • Annual percent changes in cholangiocarcinoma incidence rates were 8% for males and 11% in females.
  • Known areas of C. sinensis endemicity showed high incidence rates of cholangiocarcinoma.
  • From a meta-analysis, the summary odds ratio for cholangiocarcinoma due to C. sinensis infection was 4.7 (95% confidence interval: 2.2-9.8).
  • [MeSH-major] Bile Duct Neoplasms / epidemiology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / epidemiology. Clonorchiasis / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Female. Humans. Korea / epidemiology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1049-55 [12201863.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] Acta Trop. 2003 Nov;88(3):177-86 [14611872.001]
  • [Cites] World J Surg. 1995 Jul-Aug;19(4):637-41 [7676713.001]
  • [Cites] Int J Epidemiol. 1996 Oct;25(5):933-40 [8921477.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):136-41 [10398900.001]
  • [Cites] N Engl J Med. 1999 Oct 28;341(18):1368-78 [10536130.001]
  • [Cites] Lancet Infect Dis. 2005 Jan;5(1):31-41 [15620559.001]
  • [Cites] J Helminthol. 2005 Sep;79(3):269-81 [16153321.001]
  • [Cites] J Hepatol. 2006 Jun;44(6):1066-73 [16480786.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1751-8 [16736026.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1198-203 [16775181.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):873-5 [16788161.001]
  • [Cites] Am J Trop Med Hyg. 2006 Jul;75(1):93-6 [16837714.001]
  • [Cites] Clin Liver Dis. 2008 Feb;12(1):131-50, ix [18242501.001]
  • [Cites] Am J Gastroenterol. 2008 Jul;103(7):1716-20 [18557716.001]
  • [Cites] Korean J Parasitol. 2009 Mar;47(1):37-47 [19290090.001]
  • [Cites] Hepatogastroenterology. 2003 Jan-Feb;50(49):8-12 [12629979.001]
  • (PMID = 20592891.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2890876
  • [Keywords] NOTNLM ; Clonorchis sinensis / Korea / cholangiocarcinoma
  •  go-up   go-down


3. Nelson JW, Ghafoori AP, Willett CG, Tyler DS, Pappas TN, Clary BM, Hurwitz HI, Bendell JC, Morse MA, Clough RW, Czito BG: Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys; 2009 Jan 1;73(1):148-53
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.
  • PURPOSE: Extrahepatic cholangiocarcinoma is a rare malignancy.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / therapy. Bile Ducts, Extrahepatic. Cholangiocarcinoma / mortality. Cholangiocarcinoma / therapy. Fluorouracil / therapeutic use. Hepatectomy / statistics & numerical data. Radiotherapy, Conformal / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Male. Middle Aged. North Carolina / epidemiology. Prevalence. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Oncology (Williston Park). 2004 Jul;18(8):1049-59; discussion 1060, 1065-6, 1068 [15328897.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1977 Sep-Oct;2(9-10):883-94 [73534.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1981 Mar;7(3):413-7 [7275721.001]
  • [Cites] Cancer. 1981 Oct 15;48(8):1705-10 [7284971.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] Am J Surg. 1997 Dec;174(6):605-8; discussion 608-9 [9409582.001]
  • [Cites] J Gastrointest Surg. 2004 Nov;8(7):775-84; discussion 784 [15531230.001]
  • [Cites] Hepatogastroenterology. 2004 Nov-Dec;51(60):1612-8 [15532789.001]
  • [Cites] Eur J Surg Oncol. 2005 Jun;31(5):533-9 [15922889.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):66-74 [16372154.001]
  • [Cites] Transplantation. 2006 Dec 27;82(12):1703-7 [17198263.001]
  • [Cites] Semin Surg Oncol. 2000 Sep-Oct;19(2):156-76 [11126380.001]
  • [Cites] Lancet. 1969 Oct 25;2(7626):865-7 [4186452.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):178-82 [17276614.001]
  • [Cites] Oncology (Williston Park). 2002 Jul;16(7):939-46, 949; discussion 949-50, 952-3, 956-7 [12164560.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):414-9 [12243816.001]
  • [Cites] Abdom Imaging. 2003 May-Jun;28(3):384-91 [12719910.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1689-700 [14534886.001]
  • [Cites] Oncology. 2004;66(3):167-79 [15218306.001]
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):1-2 [19100917.001]
  • (PMID = 18805651.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K24 CA113755
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS614823; NLM/ PMC4142576
  •  go-up   go-down


Advertisement
4. Rebours V, Lévy P, Hammel P, Farges O, Ruszniewski P: [Cholangiocarcinoma due to postradiation therapy cholangitis and chronic pancreatitis]. Gastroenterol Clin Biol; 2005 Jun-Jul;29(6-7):732-4
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cholangiocarcinoma due to postradiation therapy cholangitis and chronic pancreatitis].
  • There are no reports of cholangiocarcinoma complicating post radiotherapy cholangitis.
  • During surgery, cholangiocarcinoma was discovered.
  • The patient died from his carcinoma some months later.
  • [MeSH-major] Bile Duct Neoplasms / etiology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / etiology. Cholangitis / complications. Pancreatitis / complications. Radiation Injuries / complications
  • [MeSH-minor] Adult. Chronic Disease. Humans. Male

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142009.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Lee WS, Lee KW, Heo JS, Kim SJ, Choi SH, Kim YI, Joh JW: Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today; 2006;36(10):892-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
  • PURPOSE: Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare primary hepatic neoplasm (PHN) with features of both hepatocellular and biliary differentiation.
  • We compared the outcome of hepatic resection in patients with HCC-CC, those with hepatocellular carcinoma (HCC), and those with cholangiocarcinoma (ICC).
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Follow-Up Studies. Hepatectomy. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998683.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Jhala NC, Vickers SM, Argani P, McDonald JM: Regulators of apoptosis in cholangiocarcinoma. Arch Pathol Lab Med; 2005 Apr;129(4):481-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulators of apoptosis in cholangiocarcinoma.
  • It has been previously shown that cloned Fas-negative but not Fas-positive human cholangiocarcinoma cells are resistant to anti-Fas-mediated apoptosis and develop tumors in nude mice.
  • In addition, interferon gamma induces Fas expression in Fas-negative cholangiocarcinoma cells and makes them susceptible to apoptosis.
  • Furthermore, Fas expression decreased from dysplastic epithelium to cholangiocarcinoma (P = .01), and this decreasing trend continued from well to poorly differentiated tumors.
  • [MeSH-major] Antigens, CD95 / metabolism. Apoptosis. Bile Duct Neoplasms / metabolism. Bile Duct Neoplasms / pathology. Bile Ducts, Extrahepatic / metabolism. Bile Ducts, Intrahepatic / metabolism. Cholangiocarcinoma / metabolism. Cholangiocarcinoma / pathology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunophenotyping. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794670.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


7. Unno M, Katayose Y, Rikiyama T, Yoshida H, Yamamoto K, Morikawa T, Hayashi H, Motoi F, Egawa S: Major hepatectomy for perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci; 2010 Jul;17(4):463-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Major hepatectomy for perihilar cholangiocarcinoma.
  • BACKGROUND/PURPOSE: Hilar cholangiocarcinoma and intrahepatic cholangiocarcinoma involving the hepatic hilus are defined as "perihilar cholangiocarcinoma".
  • The aim of this study was to review the outcomes of major hepatectomy for perihilar cholangiocarcinoma.
  • METHODS: Using the Kaplan-Meier method and the Cox proportional hazards model, we analyzed the results in 125 patients with perihilar cholangiocarcinoma who had undergone major hepatectomy.
  • CONCLUSIONS: Major hepatectomy for perihilar cholangiocarcinoma was acceptable and showed satisfactory outcomes.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery. Hepatectomy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Japan / epidemiology. Male. Middle Aged. Postoperative Period. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19941010.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Shi QF, Liang TB, Qin YS, Wang WL, Shen Y, Zhang M, Zheng SS: Evaluation of surgical approach for extrahepatic cholangiocarcinoma. Hepatobiliary Pancreat Dis Int; 2007 Dec;6(6):622-6
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of surgical approach for extrahepatic cholangiocarcinoma.
  • BACKGROUND: The incidence of extrahepatic cholangiocarcinoma increases in recent years.
  • This study was designed to explore the value of surgical approach in the treatment of extrahepatic cholangiocarcinoma.
  • METHODS: We retrospectively analyzed the clinical data of 135 patients with extrahepatic cholangiocarcinoma who had been treated in our hospital from January 1992 to December 2006.
  • RESULTS: The ratio of extrahepatic cholangiocarcinoma to biliary duct diseases was 1.81%.
  • CONCLUSIONS: The outcome of the patients with extrahepatic cholangiocarcinoma is still not optimistic.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086629.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S, Valdegamberi A, Capelli P, Pedica F, Nicoli P, Conci S, Iacono C: Does intrahepatic cholangiocarcinoma have better prognosis compared to perihilar cholangiocarcinoma? J Surg Oncol; 2010 Feb 1;101(2):111-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does intrahepatic cholangiocarcinoma have better prognosis compared to perihilar cholangiocarcinoma?
  • BACKGROUND AND OBJECTIVES: Cholangiocarcinoma can be classified as intrahepatic (ICC) or perihilar (PCC).
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19953578.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Alvaro D, Crocetti E, Ferretti S, Bragazzi MC, Capocaccia R, AISF Cholangiocarcinoma committee: Descriptive epidemiology of cholangiocarcinoma in Italy. Dig Liver Dis; 2010 Jul;42(7):490-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive epidemiology of cholangiocarcinoma in Italy.
  • BACKGROUND: Very little data exist on the epidemiology of cholangiocarcinoma in Italy.
  • AIM: We focus on the descriptive epidemiology of cholangiocarcinoma in Italy.
  • RESULTS: A progressive increase of incidence with age was seen for extra-hepatic, intra-hepatic and not otherwise specified cholangiocarcinoma.
  • Crude incidence rates were higher for extra-hepatic cholangiocarcinoma than those for intra-hepatic cholangiocarcinoma and in men compared to women.
  • An increasing incidence trend was observed, from 1988 to 2005, for both extra-hepatic- and intra-hepatic cholangiocarcinoma with a 3-6% yearly increase and with a rate of increase higher for men than for women and for intra-hepatic- than for extra-hepatic cholangiocarcinoma.
  • For intra-hepatic cholangiocarcinoma, the mortality rates progressively increased from 0.15 per million in 1980 to 5.9 per million in 2003, when mortality for this cancer surpassed extra-hepatic cholangiocarcinoma.
  • Mortality rates for extra-hepatic cholangiocarcinoma showed an increasing trend from 1980 to 1994 but, in contrast to intra-hepatic cholangiocarcinoma, a stable or slightly decreasing trend from 1995 to 2003 was observed.
  • CONCLUSIONS: In Italy, cholangiocarcinoma showed a progressive increase in incidence and mortality in the last two decades mainly in intra-hepatic cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Ducts, Intrahepatic. Cholangiocarcinoma / mortality
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Bile Ducts, Extrahepatic. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Italy / epidemiology. Male. Middle Aged. Sex Distribution. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20022823.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Investigator] Alvaro D; Benedetti A; Bragazzi MC; Capocaccia R; Crocetti E; Fabris L; Gianmarco F; Ferretti S; Floreani A; Grazi G; Invernizzi P; Laghi A; Mancino M; Marzioni M; Mutignani M; Paolantonio P; Sonzogni A; Strazzabosco M; Stroffolini T
  •  go-up   go-down


11. Kaneoka Y, Yamaguchi A, Isogai M, Kumada T: Survival benefit of hepatopancreatoduodenectomy for cholangiocarcinoma in comparison to hepatectomy or pancreatoduodenectomy. World J Surg; 2010 Nov;34(11):2662-70
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival benefit of hepatopancreatoduodenectomy for cholangiocarcinoma in comparison to hepatectomy or pancreatoduodenectomy.
  • BACKGROUND: Perihilar and distal cholangiocarcinoma remain difficult to treat, and long-term survival is poor.
  • We conducted a retrospective study of patients with cholangiocarcinoma to examine whether hepatopancreatoduodenectomy, in comparison to standard surgeries, provides a survival benefit.
  • METHODS: Subjects were 75 patients with perihilar or distal cholangiocarcinoma who, between April 1997 and May 2007, underwent hepatectomy with bile duct resection (Hx, n = 29), pancreatoduodenectomy (PD, n = 32), or hepatopancreatoduodenectomy (HPD, n = 14) at our hospital.
  • CONCLUSIONS: In cases of perihilar or distal cholangiocarcinoma, aggressive surgery must be aimed at overcoming perineural invasion.
  • Our findings indicate that HPD improves survival of patients undergoing surgery for widespread cholangiocarcinoma in comparison to standard surgeries.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery. Hepatectomy / mortality. Pancreaticoduodenectomy / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20607255.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Ebata T, Kamiya J, Nishio H, Nagasaka T, Nimura Y, Nagino M: The concept of perihilar cholangiocarcinoma is valid. Br J Surg; 2009 Aug;96(8):926-34
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The concept of perihilar cholangiocarcinoma is valid.
  • BACKGROUND: The term perihilar cholangiocarcinoma has been used for all tumours involving or requiring resection of the hepatic confluence.
  • This retrospective study examined whether the concept of perihilar cholangiocarcinoma is valid clinically.
  • METHODS: Some 250 patients with perihilar cholangiocarcinoma were divided into extrahepatic (EHC, 167 patients) and intrahepatic (IHC, 83) groups based on tumour location.
  • CONCLUSION: Combining EHC and IHC under the term perihilar cholangiocarcinoma is valid, as these tumours have comparable biological behaviour, with similar clinical management depending on stage and invasion.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Extrahepatic / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Neoplasm Staging / mortality. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 19591162.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Yeh CN, Jan YY, Chen MF: Hepatectomy for peripheral cholangiocarcinoma in elderly patients. Ann Surg Oncol; 2006 Dec;13(12):1553-9
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatectomy for peripheral cholangiocarcinoma in elderly patients.
  • BACKGROUND: Peripheral cholangiocarcinoma (CCC) is less common than hepatocellular carcinoma.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery. Hepatectomy / methods
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009157.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Flood WA, Lewis LD: A phase I study of intravenous (IV) milataxel in combination with carboplatin in adult patients with advanced malignant solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13525

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of intravenous (IV) milataxel in combination with carboplatin in adult patients with advanced malignant solid tumors.
  • The primary objective of this study was to determine the MTD when MXL was given intravenously in combination with a fixed dose (AUC=6) of carboplatin (C) every 21 days in subjects with advanced malignant solid tumors.
  • METHODS: Key subject eligibility criteria included: adult pts with refractory malignant tumors, ECOG PS <3 and adequate hematologic, hepatic and renal function.
  • One pt in the MTD cohort with cholangiocarcinoma had a PR.
  • One patient with a cholangiocarcinoma had a sustained PR for 378 days.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961283.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Urahashi T, Yamamoto M, Ohtsubo T, Katsuragawa H, Katagiri S, Takasaki K: Hepatopancreatoduodenectomy could be allowed for patients with advanced intrahepatic cholangiocarcinoma. Hepatogastroenterology; 2007 Mar;54(74):346-9
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatopancreatoduodenectomy could be allowed for patients with advanced intrahepatic cholangiocarcinoma.
  • BACKGROUND/AIMS: Patients with advanced intrahepatic cholangiocarcinoma (ICC) have a poor outcome even if they undergo extended radical surgery.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery. Hepatectomy. Pancreaticoduodenectomy
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness. Survival Rate

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523271.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


16. Koh KC, Lee H, Choi MS, Lee JH, Paik SW, Yoo BC, Rhee JC, Cho JW, Park CK, Kim HJ: Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg; 2005 Jan;189(1):120-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma.
  • BACKGROUND: Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma (HCC-CC) have not been established.
  • METHODS: Data of patients who underwent surgical resection for HCC-CC were compared with those of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (CC) patients.
  • [MeSH-major] Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / mortality. Cholangiocarcinoma / pathology. Liver Neoplasms / mortality. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701504.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Mall AS, Tyler MG, Ho SB, Krige JE, Kahn D, Spearman W, Myer L, Govender D: The expression of MUC mucin in cholangiocarcinoma. Pathol Res Pract; 2010 Dec 15;206(12):805-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of MUC mucin in cholangiocarcinoma.
  • Cholangiocarcinoma (CC) is a highly malignant epithelial cancer of the biliary tract, the cellular and molecular pathogenesis of which remains unclear.
  • Extensive MUC3 expression was significantly associated with well-differentiated tumors, whilst there was an approaching significance between the extensive expression of MUC1 and metastasis in cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / chemistry. Bile Ducts, Intrahepatic / chemistry. Biomarkers, Tumor / analysis. Cholangiocarcinoma / chemistry. Mucins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mucin 5AC / analysis. Mucin-1 / analysis. Mucin-2 / analysis. Mucin-3 / analysis. Mucin-4 / analysis. Mucin-6 / analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20947262.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / MUC2 protein, human; 0 / MUC3A protein, human; 0 / MUC4 protein, human; 0 / MUC5AC protein, human; 0 / MUC6 protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucin-3; 0 / Mucin-4; 0 / Mucin-6; 0 / Mucins
  •  go-up   go-down


18. Li FH, Chen XQ, Luo HY, Li YH, Wang F, Qiu MZ, Teng KY, Li ZH, Xu RH: [Prognosis of 84 intrahepatic cholangiocarcinoma patients]. Ai Zheng; 2009 May;28(5):528-32
Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis of 84 intrahepatic cholangiocarcinoma patients].
  • BACKGROUND AND OBJECTIVE: The incidence of intrahepatic cholangiocarcinoma (ICC) is low.
  • [MeSH-minor] Adult. Aged. Bile Duct Neoplasms / blood. Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Bilirubin / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Chemotherapy, Adjuvant. Cholangiocarcinoma / blood. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Female. Follow-Up Studies. Humans. Liver Neoplasms / blood. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neoplastic Cells, Circulating. Palliative Care. Proportional Hazards Models. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624884.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


19. Li Q, Wang JM, Liu C, Xiao BL, Su Y, Zou SQ: [Expression and significance of aPKC-iota and E-cadherin in cholangiocarcinoma]. Ai Zheng; 2007 Jul;26(7):715-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of aPKC-iota and E-cadherin in cholangiocarcinoma].
  • This study was to investigate the expression of aPKC-iota and E-cadherin in cholangiocarcinoma, and analyze molecular mechanisms of the invasion and metastasis of cholangiocarcinoma.
  • METHODS: The expression of aPKC-iota and E-cadherin in 9 specimens of benign bile duct tissues and 35 specimens of cholangiocarcinoma was detected by EnVision immunohistochemistry, and their correlations to the clinicopathologic characteristics and invasion of cholangiocarcinoma were analyzed.
  • RESULTS: The positive rate of aPKC-iota was significantly higher in cholangiocarcinoma than in benign bile duct tissues (68.6% vs. 11.1%, P = 0.006), while the positive rate of E-cadherin was significantly lower in cholangiocarcinoma than in benign bile duct tissues (37.1% vs. 88.9%, P = 0.016).
  • aPKC-iota expression was positively and E-cadherin expression was negatively correlated to the differentiation and invasion of cholangiocarcinoma (P < 0.05).
  • CONCLUSIONS: The expression of aPKC-iota and E-cadherin may reflect the differentiation and invasive potential of cholangiocarcinoma.
  • As a polar regulation-associated protein, aPKC-iota may play a role in the invasion and metastasis of cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic. Cadherins / metabolism. Cholangiocarcinoma / metabolism. Isoenzymes / metabolism. Protein Kinase C / metabolism
  • [MeSH-minor] Adult. Aged. Bile Ducts / metabolism. Cell Differentiation. Cholangitis / metabolism. Choledochal Cyst / metabolism. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17626746.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cadherins; 0 / Isoenzymes; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / protein kinase C lambda
  •  go-up   go-down


20. Shimizu Y, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M: The morbidity, mortality, and prognostic factors for ampullary carcinoma and distal cholangiocarcinoma. Hepatogastroenterology; 2008 Mar-Apr;55(82-83):699-703
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The morbidity, mortality, and prognostic factors for ampullary carcinoma and distal cholangiocarcinoma.
  • BACKGROUND/AIMS: Ampullary carcinoma and distal cholangiocarcinoma are potentially more amenable to pancreaticoduodenectomy for long-term survival than pancreatic carcinoma.
  • The aims of this study are to evaluate experience with ampullary carcinoma and distal cholangiocarcinoma at a single institution.
  • METHODOLOGY: Seventy-two consecutive patients with ampullary carcinoma and distal cholangiocarcinoma who underwent radical resection at Chiba University Hospital from 1985 to 2001.
  • RESULTS: Pancreaticoduodenectomy was performed in 37 of 38 patients for ampullary carcinoma and 29 of 34 patients for distal cholangiocarcinoma.
  • The morbidity rates of patients with ampullary carcinoma and distal cholangiocarcinoma were 21.1% and 20.6%, and mortality rates were 0% and 2.9%, respectively.
  • The cumulative 5-year survival rates in cases of ampullary carcinoma and distal cholangiocarcinoma were 63% and 45%, respectively.
  • By univariate analysis, pancreatic invasion, lymph node metastasis, and duodenal invasion were significant prognostic factors for ampullary carcinoma.
  • Perineural invasion and histological grade, but not lymph node metastasis, were significant factors for distal cholangiocarcinoma.
  • Multivariate analysis indicated that lymph node metastasis was the only independent prognostic factor for ampullary carcinoma, and that perineural invasion was the only independent prognostic factor for distal cholangiocarcinoma.
  • CONCLUSIONS: The overall mortality of 1.4% and the cumulative 5-year survival rates for ampullary carcinoma and distal cholangiocarcinoma are acceptable.
  • Ampullary carcinoma with lymph node metastasis and distal cholangiocarcinoma with perineural invasion have higher risk of recurrence.
  • [MeSH-major] Ampulla of Vater. Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / mortality. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Postoperative Complications / epidemiology. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613437.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


21. Tischoff I, Tannapfel A: [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy]. Zentralbl Chir; 2007 Aug;132(4):300-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy].
  • Primary liver cancer is one of the most common cancer worldwide.
  • Beside hepatocellular carcinoma (HCC), accounting for more than 80%, cholangiocarcinoma (CC) is the second most frequent primary malignant epithelial liver tumor.
  • Combined hepatocellular-cholangiocarcinoma (HCC/CC) is a rare form of liver cancer with a frequency of 1%.
  • Both, hepatocellular carcinoma and cholangiocarcinoma, show a wide geographical variation with low-incidence areas in North America and Europe and high incidence areas in Africa and Asia.
  • 70-80% of hepatocellular carcinoma occur in cirrhotic liver.
  • The etiology of cholangiocarcinoma remains unclear, most occur in absence of known etiological factors.
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular. Cholangiocarcinoma. Liver Neoplasms
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Incidence. Liver / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724632.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 33
  •  go-up   go-down


22. Park SY, Roh SJ, Kim YN, Kim SZ, Park HS, Jang KY, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact. Oncol Rep; 2009 Sep;22(3):649-57
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact.
  • The aim of this study was to determine the relationship between the expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma and clinicopathological parameters as well as patient survival.
  • In addition, this study was performed to identify whether immunohistochemical staining for mucins is useful to differentiate cholangiocarcinoma from adenocarcinoma of the pancreas and gallbladder.
  • Immunohistochemical staining for MUC1, MUC2, MUC5AC and MUC6 was performed for 85 cases of cholangiocarcinoma, including 34 cases of intrahepatic cholangiocarcinoma (ICC), 51 cases of extrahepatic cholangiocarcinoma (ECC), 11 cases of gallbladder adenocarcinoma and 14 cases of pancreas adenocarcinoma.
  • Our results suggest that the expression of MUC1 might be associated with the progression of cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / chemistry. Bile Ducts, Intrahepatic. Cholangiocarcinoma / chemistry. Mucin 5AC / analysis. Mucin-1 / analysis. Mucin-2 / analysis. Mucin-6 / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639217.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / MUC1 protein, human; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / MUC6 protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucin-6
  •  go-up   go-down


23. Forsmo HM, Horn A, Viste A, Hoem D, Ovrebo K: Survival and an overview of decision-making in patients with cholangiocarcinoma. Hepatobiliary Pancreat Dis Int; 2008 Aug;7(4):412-7
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and an overview of decision-making in patients with cholangiocarcinoma.
  • BACKGROUND: Cholangiocarcinoma is rare, accounting for approximately 3% of all gastrointestinal cancers.
  • METHODS: A total of 121 patients, 55 men and 66 women, median age 70 years (range 31-91), who had been treated for cholangiocarcinoma in the period of 1990-2005 were evaluated retrospectively.
  • Age above 65 years (OR 3.4; 95% CI 1.4-8.4; P=0.008), weight loss (OR 8.5; 95% CI 1.5-46; P=0.01) or tumour location (The resection rate of hilar cholangiocarcinoma was lower than that of intrapancreatic cancer.
  • CONCLUSIONS: In few patients with a resectable cholangiocarcinoma, an explorative laparotomy is often necessary to evaluate resectability.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / mortality. Hepatectomy. Palliative Care. Patient Selection
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Norway / epidemiology. Retrospective Studies. Risk Assessment. Risk Factors. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18693178.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Chiou YY, Hwang JI, Chou YH, Wang HK, Chiang JH, Chang CY: Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinoma. Kaohsiung J Med Sci; 2005 Jul;21(7):304-9
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinoma.
  • This study evaluated the clinical applications, treatment effects, and complications of percutaneous ultrasound (US)-guided radiofrequency ablation (RFA) of intrahepatic cholangiocarcinoma.
  • Ten patients (6 men and 4 women) with histologically proven cholangiocarcinoma underwent US-guided percutaneous RFA.
  • In conclusion, percutaneous RFA is effective and successful in the treatment of intrahepatic cholangiocarcinoma of 3 cm or less and satisfactory for tumors of 3-5 cm.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / ultrasonography. Catheter Ablation / methods. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16089307.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


25. Lai EC, Lau WY: Aggressive surgical resection for hilar cholangiocarcinoma. ANZ J Surg; 2005 Nov;75(11):981-5
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive surgical resection for hilar cholangiocarcinoma.
  • BACKGROUND: Surgical treatment of hilar cholangiocarcinoma remains a great challenge to surgeons because of its low resectability, poor survival, and high operative mortality and morbidity.
  • METHODS: The medical and pathological records of 36 patients with a preoperative diagnosis of 'resectable' hilar cholangiocarcinoma operated on by us between January 1998 and December 2002 were studied.
  • CONCLUSIONS: Aggressive surgery increases the resectability of hilar cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatectomy. Humans. Liver Transplantation. Male. Middle Aged. Retrospective Studies. Survival Rate. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16336393.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


26. Okuda H, Shiratori K, Yamamoto M, Takasaki K, Nakano M: Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol; 2006 May;21(5):869-73
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
  • BACKGROUND: Some patients who are seropositive for lectin-reactive alpha-fetoprotein (AFP-L3) have intrahepatic cholangiocarcinoma (ICC).
  • The features of combined hepatocellular and cholangiocarcinoma (n = 11) were also studied.
  • More patients in group A were misdiagnosed as having hepatocellular carcinoma (HCC) at surgery (70%vs 5.7%, P < 0.001) who also had chronic liver disease (80%vs 25.7%, P < 0.01) than in group B.
  • Seven, 10 and 11 of the 11 patients with combined hepatocellular and cholangiocarcinoma were seropositive for AFP-L3, CA 19-9 and hepatitis viruses, respectively.
  • CONCLUSIONS: Patients with ICC seropositive for AFP-L3 and those with combined hepatocellular and cholangiocarcinoma have features close to HCC.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CA-19-9 Antigen / metabolism. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16704538.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / alpha-Fetoproteins
  •  go-up   go-down


27. Hur H, Park IY, Sung GY, Lee DS, Kim W, Won JM: Intrahepatic cholangiocarcinoma associated with intrahepatic duct stones. Asian J Surg; 2009 Jan;32(1):7-12
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrahepatic cholangiocarcinoma associated with intrahepatic duct stones.
  • OBJECTIVE: It has been well established that the long-term prognosis of intrahepatic duct stones (IHDS) is complicated by the late development of biliary cirrhosis with associated intrahepatic cholangiocarcinoma (IHCC).
  • Therefore, while performing diagnostic studies and surgery for IHDS, one should always consider the possibility of coexisting cholangiocarcinoma.

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19321396.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


28. Kopek N, Holt MI, Hansen AT, Høyer M: Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol; 2010 Jan;94(1):47-52
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic body radiotherapy for unresectable cholangiocarcinoma.
  • PURPOSE: To report outcomes of a single institution study of stereotactic body radiotherapy (SBRT) for unresectable cholangiocarcinoma.
  • METHODS AND MATERIALS: Twenty-seven patients with unresectable cholangiocarcinoma (n=26 Klatskin tumours and one intrahepatic cholangiocarcinoma (IHCC)) were treated by linac-based SBRT.
  • CONCLUSION: The outcomes of SBRT for unresectable cholangiocarcinoma appear comparable to conventionally fractionated chemoradiotherapy with or without brachytherapy boost.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery. Radiosurgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19963295.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


29. He F, Yan Q, Fan L, Liu Y, Cui J, Wang J, Wang L, Wang Y, Wang Z, Guo Y, Huang G: PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma. Hum Pathol; 2010 Mar;41(3):415-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma.
  • In this study, we analyzed PBK/TOPK expression in hepatic primary tumor and explored its role in cholangiocarcinoma biology.
  • The protein, mRNA of PBK/TOPK, and cell cycle of cholangiocarcinoma cell line after PBK/TOPK suppression with small interfere RNA were studied by Western blot, semiquantitative reverse transcriptase-polymerase chain reaction, and flow cytometry, respectively.
  • PBK/TOPK was usually expressed in normal bile duct epithelial cells and much more frequently expressed in cholangiocarcinoma (68/74) but never expressed in hepatocytes and hepatocellular carcinomas (0/33).
  • PBK/TOPK down-regulation was related to the poor prognosis of patients with cholangiocarcinoma (P = .013).
  • Epidermal growth factor can enhance PBK/TOPK expression in cholangiocarcinoma QBC 939 cells, but suppression of PBK/TOPK in the cells did not affect their proliferation.
  • PBK/TOPK protein could serve as a useful indicator for histopathologic differentiation between cholangiocarcinoma and hepatocellular carcinomas and the low expression of PBK/TOPK is predicative of poor survival in cholangiocarcinoma patients.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Cholangiocarcinoma / diagnosis. Liver Neoplasms / diagnosis. Protein-Serine-Threonine Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Bile Ducts / metabolism. Blotting, Western. Cell Cycle / physiology. Cell Line, Tumor. Cells, Cultured. Diagnosis, Differential. Epithelial Cells / metabolism. Female. Flow Cytometry. Gene Silencing. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Mitogen-Activated Protein Kinase Kinases. Prognosis. Proportional Hazards Models. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sex Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19954816.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 2.7.12.2 / PDZ-binding kinase
  •  go-up   go-down


30. Zhang BH, Cheng QB, Luo XJ, Zhang YJ, Jiang XQ, Zhang BH, Yi B, Yu WL, Wu MC: Surgical therapy for hiliar cholangiocarcinoma: analysis of 198 cases. Hepatobiliary Pancreat Dis Int; 2006 May;5(2):278-82
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical therapy for hiliar cholangiocarcinoma: analysis of 198 cases.
  • BACKGROUND: Carcinoma of the hepatic duct confluence is the most common site of bile duct malignancies.
  • Although hilar cholangiocarcinoma has been characterized as a slow-growing and late metastasizing tumor, post-therapeutic prognosis has remained poor.
  • The study was undertaken to analyze factors influencing the surgical curative effect of hilar cholangiocarcinoma.
  • METHODS: A retrospective clinical analysis was made of 198 patients with hilar cholangiocarcinoma who had been surgically treated at our hospital from 1997 to 2002.
  • CONCLUSION: Early diagnosis and radical resection are important to improve the prognosis of hilar cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Biliary Tract Surgical Procedures / methods. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Palliative Care. Retrospective Studies. Risk Assessment. Sex Factors. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698591.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  •  go-up   go-down


31. Geng XP, Zhu HG, Liu FB, Hou H, Zhang ZG, Zhao HC, Wang GB, Zhao YJ: [Anatomy problems in the radical resection for hilar cholangiocarcinoma]. Zhonghua Wai Ke Za Zhi; 2009 Aug 1;47(15):1167-70
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anatomy problems in the radical resection for hilar cholangiocarcinoma].
  • OBJECTIVE: To analyze the clinical data, surgical strategies and results from the patients with hilar cholangiocarcinoma (HCCA), and to explore the anatomic factors related to the radical resection.
  • CONCLUSIONS: Some anatomical factors should be considered during the radical resection of hilar cholangiocarcinoma, especially evaluation of potential hepatectomy, resection of caudate lobe, hepatic artery resection and/or reconstruction.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Hepatectomy. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021909.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


32. Igami T, Nagino M, Oda K, Nishio H, Ebata T, Yokoyama Y, Shimoyama Y: Clinicopathologic study of cholangiocarcinoma with superficial spread. Ann Surg; 2009 Feb;249(2):296-302
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic study of cholangiocarcinoma with superficial spread.
  • OBJECTIVE: To review our experience with cholangiocarcinoma with superficial spread, to clarify its clinical features, and to discuss treatment strategies.
  • SUMMARY BACKGROUND DATA: Most of the previous reports on cholangiocarcinoma with superficial spread were case reports.
  • Little is known about this type of cholangiocarcinoma.
  • METHODS: The medical records of 471 patients with cholangiocarcinoma who underwent resection (351 perihilar and 120 distal cancers) were retrospectively reviewed, focusing on superficial spread, which was defined as noninvasive cancer extension of more than 20 mm.
  • All positive proximal ductal margins in C(+SS) were because of carcinoma in situ, whereas invasive cancer was the main reason for positivity in C(-SS).
  • Survival was comparable between the patients with a negative ductal margin and those with a positive margin with carcinoma in situ.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatectomy. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212185.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Liang LJ, Lai JM, Li SQ, Peng BG, Yin XY, Tang D, Lü MD, Huang JF: [Experience of surgical resection of 103 hilar cholangiocarcinoma]. Zhonghua Wai Ke Za Zhi; 2006 Jul 1;44(13):882-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experience of surgical resection of 103 hilar cholangiocarcinoma].
  • OBJECTIVE: To summarize the experience of surgical resection of 103 hilar cholangiocarcinoma.
  • METHODS: One hundred and three consecutive cases of hilar cholangiocarcinoma who underwent surgical resection at our hospital over the past ten years were reviewed retrospectively.
  • Radical resection can improve postoperative survival, and produce a satisfactory outcome for patient with hepatic hilar cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery. Digestive System Surgical Procedures / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17067476.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


34. Yu WL, Zhang YJ, Dong H, Yu H, Xian ZH, Wu MC, Cong WM: [Biopathological characteristics of hilar cholangiocarcinoma and the clinical significance]. Zhonghua Wai Ke Za Zhi; 2009 Aug 1;47(15):1162-6
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biopathological characteristics of hilar cholangiocarcinoma and the clinical significance].
  • OBJECTIVE: To approach the biopathological features of hilar cholangiocarcinoma and surgical pathological factors which influence the long-term survivals of patients with hilar cholangiocarcinoma.
  • METHODS: A systemic and retrospective multi-parameter analysis was performed on 205 patients of hilar cholangiocarcinoma who received surgical treatments and had complete clinicopathological data as well as follow-up results during a ten-year-period from April 1998 to April 2008.
  • CONCLUSIONS: The most important prognostic factors influencing the long-term survivals of patients with hilar cholangiocarcinoma after operation are lymph node metastasis and depth of tumor-infiltrating of involved bile duct.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Hepatectomy. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021908.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


35. Paik KY, Jung JC, Heo JS, Choi SH, Choi DW, Kim YI: What prognostic factors are important for resected intrahepatic cholangiocarcinoma? J Gastroenterol Hepatol; 2008 May;23(5):766-70
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What prognostic factors are important for resected intrahepatic cholangiocarcinoma?
  • BACKGROUND AND AIM: Our aim was to evaluate the predictive factors for survival and disease-free survival of patients with resected intrahepatic cholangiocarcinoma (ICC).
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / mortality. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868336.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


36. Uhm KO, Park YN, Lee JY, Yoon DS, Park SH: Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization. Cancer Genet Cytogenet; 2005 Feb;157(1):37-41
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization.
  • Intrahepatic cholangiocarcinoma (ICC) arises from epithelial cells in the intrahepatic bile duct.
  • [MeSH-major] Bile Duct Neoplasms / genetics. Bile Ducts, Intrahepatic. Cholangiocarcinoma / genetics. Chromosome Aberrations. Nucleic Acid Hybridization / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15676145.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Sano T, Shimada K, Sakamoto Y, Ojima H, Esaki M, Kosuge T: Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus. Ann Surg Oncol; 2008 Feb;15(2):590-9
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus.
  • BACKGROUND: Clinically hepatobiliary resection is indicated for both hilar bile duct cancer (BDC) and intrahepatic cholangiocarcinoma involving the hepatic hilus (CCC).
  • METHODS: Between 1990 and 2004, we surgically treated 158 consecutive patients with perihilar cholangiocarcinoma.
  • Therefore, differentiating between these two categories must impact the prediction of postoperative survival in patients with perihilar cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Ducts, Intrahepatic. Cholangiocarcinoma / mortality
  • [MeSH-minor] Adult. Cell Differentiation. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / mortality. Prognosis. Proportional Hazards Models. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057991.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Dinant S, Gerhards MF, Rauws EA, Busch OR, Gouma DJ, van Gulik TM: Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor). Ann Surg Oncol; 2006 Jun;13(6):872-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor).
  • BACKGROUND: Treatment of hilar cholangiocarcinoma (Klatskin tumors) has changed in many aspects.
  • METHODS: A total of 99 consecutive patients underwent resection for hilar cholangiocarcinoma in three 5-year time periods: periods 1 (1988-1993; n=45), 2 (1993-1998; n=25), and 3 (1998-2003; n=29).
  • [MeSH-major] Bile Duct Neoplasms / surgery. Biliary Tract Surgical Procedures. Cholangiocarcinoma / surgery. Hepatic Duct, Common / surgery. Klatskin Tumor / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Hepatectomy. Humans. Lymph Nodes / pathology. Male. Middle Aged. Palliative Care. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Klatskin tumor.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614876.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Zhang L, Cai JQ, Bi XY, Zhao JJ, Xing GS, Yan T, Fu YX, Zhao P: [Analysis of prognostic factors influencing the outcome of intrahepatic cholangiocarcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Nov;31(11):845-8
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of prognostic factors influencing the outcome of intrahepatic cholangiocarcinoma].
  • OBJECTIVE: To analyze the clinicopathologic factors influencing the outcome of surgically treated intrahepatic cholangiocarcinoma (ICC) and to explore the proper treatment choice of ICC.
  • Radical resection is still the optimal treatment for patient with intrahepatic cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery. Hepatectomy / methods
  • [MeSH-minor] Adult. Aged. Carcinoembryonic Antigen / blood. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Rate. Tumor Burden

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137350.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


40. Javle MM, Yu J, Khoury T, Chadha KS, Iyer RV, Foster J, Kuvshinoff BW, Gibbs JF, Geradts J, Black JD, Brattain MG: Akt expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol; 2006 Nov;21(11):1744-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Akt expression may predict favorable prognosis in cholangiocarcinoma.
  • BACKGROUND: Overexpression of signaling proteins including epidermal growth factor receptor (EGFR), Akt, mitogen activated protein kinase (MAPK) and cyclooxygenase-2 (COX-2) occurs in cholangiocarcinoma cell lines.
  • The aim of this clinicopathological study was to investigate the overexpression and co-expression of EGFR and related signaling proteins in cholangiocarcinoma and explore their relationship to clinical outcome.
  • METHODS: Twenty-four consecutive cases of cholangiocarcinoma treated from 1996 to 2002 at Roswell Park Cancer Institute were included.
  • CONCLUSION: Epidermal growth factor receptor signaling intermediates are commonly expressed in cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic. Cholangiocarcinoma / metabolism. Proto-Oncogene Proteins c-akt / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Cyclooxygenase 2 / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Mitogen-Activated Protein Kinases / metabolism. Prognosis. Proportional Hazards Models. Receptor, Epidermal Growth Factor / metabolism. SEER Program. Signal Transduction

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Gastroenterol Hepatol. 2007 Jan;22(1):145. Chadha, Krishdeep C [corrected to Chadha, Krishdeep S]
  • (PMID = 16984600.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16056; United States / NCI NIH HHS / CA / CA62502
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


41. Hemming AW, Kim RD, Mekeel KL, Fujita S, Reed AI, Foley DP, Howard RJ: Portal vein resection for hilar cholangiocarcinoma. Am Surg; 2006 Jul;72(7):599-604; discussion 604-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Portal vein resection for hilar cholangiocarcinoma.
  • Hilar cholangiocarcinoma remains a difficult challenge for the surgeon.
  • This study reviews the results of portal vein resection for hilar cholangiocarcinoma.
  • Between 1998 and 2005, 60 patients underwent potentially curative resections of hilar cholangiocarcinoma.
  • Portal vein resection for hilar cholangiocarcinoma is safe and allows a chance for long-term survival in otherwise unresectable patients.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery. Portal Vein / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cause of Death. Female. Follow-Up Studies. Hepatectomy. Hepatic Artery / surgery. Humans. Male. Microsurgery. Middle Aged. Pancreaticoduodenectomy. Postoperative Complications. Reconstructive Surgical Procedures. Retrospective Studies. Safety. Surgical Wound Infection / etiology. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875081.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Li SQ, Liang LJ, Hua YP, Peng BG, He Q, Lu MD, Chen D: Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma. Chin Med J (Engl); 2009 Oct 5;122(19):2286-91
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma.
  • BACKGROUND: The management of intrahepatic cholangiocarcinoma (ICC) remains a challenge due to poor prognosis.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Ducts, Intrahepatic. Cholangiocarcinoma / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079127.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


43. Portolani N, Baiocchi GL, Coniglio A, Piardi T, Grazioli L, Benetti A, Ferrari Bravo A, Giulini SM: Intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a Western experience. Ann Surg Oncol; 2008 Jul;15(7):1880-90
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a Western experience.
  • BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is an unusual tumour.
  • METHODS: The clinicopathological data of 67 patients with ICC and combined hepatocellular-cholangiocarcinoma (HCC-ICC) are presented.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatitis B / complications. Hepatitis C / complications. Humans. Liver Cirrhosis / complications. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary. Prognosis. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443881.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Giuliante F, Ardito F, Vellone M, Nuzzo G: Liver resections for hilar cholangiocarcinoma. Eur Rev Med Pharmacol Sci; 2010 Apr;14(4):368-70
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resections for hilar cholangiocarcinoma.
  • Hilar cholangiocarcinoma (HC) is a rare tumor which has to be distinguished by intrahepatic cholagiocarcinoma invading hepatic hilum because the former has better prognosis then the latter.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Cholangiocarcinoma / surgery. Liver / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496550.001).
  • [ISSN] 1128-3602
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


45. Gomez D, Morris-Stiff G, Toogood GJ, Lodge JP, Prasad KR: Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol; 2008 May 1;97(6):513-8
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma.
  • AIMS: To analyse the results and prognostic factors affecting disease-free and overall survival following potentially curative resection for intrahepatic cholangiocarcinoma (IHCC).
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery. Inflammation / physiopathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18335453.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Kim JW, Jo S, Moon HJ, Heo JS, Choi SH, Joh JW, Choi DW, Chung JC, Kim YI: [Prognostic factors after major resection for distal extrahepatic cholangiocarcinoma]. Korean J Gastroenterol; 2006 Feb;47(2):144-52
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors after major resection for distal extrahepatic cholangiocarcinoma].
  • Thus, we evaluated the outcomes and prognostic factors after major resection for distal extrahepatic cholangiocarcinoma (dCC).
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Biliary Tract Surgical Procedures. Female. Humans. Male. Middle Aged. Prognosis. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498281.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


47. Xu H, Inagaki Y, Tang W, Guo Q, Wang F, Seyama Y, Midorikawa Y, Gai R, Kokudo N, Sugawara Y, Nakata M, Makuuchi M: Elevation of serum KL-6 mucin levels in patients with cholangiocarcinoma. Hepatogastroenterology; 2008 Nov-Dec;55(88):2000-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of serum KL-6 mucin levels in patients with cholangiocarcinoma.
  • Previous immunohistochemical studies by the authors revealed that, in liver cancer tissues, KL-6 mucin expressed only in intrahepatic cholangiocarcinoma (CC) but not in hepatocellular carcinoma (HCC).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Liver / metabolism. Male. Middle Aged. ROC Curve

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260467.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / MUC1 protein, human; 0 / Mucin-1
  •  go-up   go-down


48. Shinohara ET, Guo M, Mitra N, Metz JM: Brachytherapy in the treatment of cholangiocarcinoma. Int J Radiat Oncol Biol Phys; 2010 Nov 1;78(3):722-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brachytherapy in the treatment of cholangiocarcinoma.
  • METHODS AND MATERIALS: Using the Surveillance, Epidemiology and End Results database, a total of 193 patients with cholangiocarcinoma treated with brachytherapy were identified for the period 1988-2003.
  • The primary analysis compared patients treated with brachytherapy (with or without external-beam radiation) with those who did not receive radiation.
  • [MeSH-major] Bile Duct Neoplasms / radiotherapy. Bile Ducts, Intrahepatic. Brachytherapy. Cholangiocarcinoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20207503.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Borie F, Niampa H, Bouvier AM, Faivre J, Launoy G, Delafosse P, Velten M, Buemi A, Peng J, Grosclaude P, Trétarre B: [Current management and prognosis of intrahepatic cholangiocarcinoma in France]. Gastroenterol Clin Biol; 2009 Oct-Nov;33(10-11):971-6
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current management and prognosis of intrahepatic cholangiocarcinoma in France].
  • INTRODUCTION: Intrahepatic cholangiocarcinoma (ICC) is a rare tumor with a poor prognosis.
  • METHODS: Between 1997 and 1998, 1100 cases of primary liver cancer were observed in nine French departments: 68 were ICC.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / mortality. Cholangiocarcinoma / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. France / epidemiology. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Radiotherapy, Adjuvant. Registries. Survival Analysis

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19647386.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


50. Liu L, Wang J, Liu B, Dai S, Wang X, Chen J, Huang L, Xiao X, He D: Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma. J Cell Biochem; 2008 Jun 1;104(3):745-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma.
  • BACKGROUND: Cholangiocarcinoma (CC) is devastating neoplasm and very few specific biomarkers could be used in clinical diagnosis.
  • [MeSH-major] Bile Duct Neoplasms / blood. Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic / metabolism. Cholangiocarcinoma / blood. Cholangiocarcinoma / metabolism. Gene Expression Regulation, Neoplastic. Prealbumin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. CA-19-9 Antigen / biosynthesis. Case-Control Studies. Female. Humans. Male. Middle Aged


56. Aishima S, Kuroda Y, Asayama Y, Taguchi K, Nishihara Y, Taketomi A, Tsuneyoshi M: Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma. Hum Pathol; 2006 Mar;37(3):283-91
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma.
  • Combined hepatocellular and cholangiocarcinoma (cHC-CC) is a rare type of liver cancer displaying both hepatocellular and cholangiocellular components.
  • The cholangiocellular carcinoma (CC) in these tumors ranges from focal to prominent.
  • The Ki-67 labeling index values for the hepatocellular carcinoma, CC, and sarcomatous components were 11.4% +/- 12.9%, 25.4% +/- 18.3%, and 46.0% +/- 23.6%, respectively.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / secondary. Cholangiocarcinoma / secondary. Liver Neoplasms / pathology. Sarcoma / secondary
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasms, Multiple Primary. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613323.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


57. Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S, Valdegamberi A, Nicoli P, Cappellani A, Malfermoni G, Iacono C: Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg; 2009 Jun;33(6):1247-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.
  • BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Ducts, Intrahepatic. Cholangiocarcinoma / mortality. Hepatectomy / methods. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Longitudinal Studies. Male. Middle Aged. Multivariate Analysis. Prognosis. Risk Factors. Survival Rate. Treatment Outcome


58. Zhou HB, Wang H, Zhou DX, Wang H, Wang Q, Zou SS, Hu HP: Etiological and clinicopathologic characteristics of intrahepatic cholangiocarcinoma in young patients. World J Gastroenterol; 2010 Feb 21;16(7):881-5
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etiological and clinicopathologic characteristics of intrahepatic cholangiocarcinoma in young patients.
  • AIM: To investigate the prevalence, risk factors, and clinicopathologic characteristics of intrahepatic cholangiocarcinoma (ICC) in young patients.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / etiology. Bile Ducts, Intrahepatic / pathology. Biomarkers, Tumor / blood. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / etiology
  • [MeSH-minor] Adult. Age Factors. Aged. Female. Hepatitis B / complications. Hepatitis C / complications. Humans. Lithiasis / complications. Liver Cirrhosis / virology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prevalence. Retrospective Studies. Risk Assessment. Risk Factors. Schistosomiasis / complications. Young Adult

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2000 Jan;31(1):7-11 [10613720.001]
  • [Cites] Hepatology. 2009 Jan;49(1):116-23 [19085911.001]
  • [Cites] J Pathol. 2000 Sep;192(1):43-51 [10951399.001]
  • [Cites] Br J Surg. 2002 Aug;89(8):962-70 [12153620.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1049-55 [12201863.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] World J Gastroenterol. 2004 Feb 1;10(3):427-32 [14760772.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Apr 1;19(7):771-7 [15043518.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):115-25 [15192785.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):592-5 [15245596.001]
  • [Cites] Int J Epidemiol. 1996 Oct;25(5):933-40 [8921477.001]
  • [Cites] Hepatology. 1998 Oct;28(4):921-5 [9755226.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):620-6 [15765398.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Mar;21(3):588-94 [16638104.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1073-8 [16679351.001]
  • [Cites] Oncologist. 2007 Mar;12(3):320-4 [17405896.001]
  • [Cites] Am J Gastroenterol. 2007 May;102(5):1016-21 [17324130.001]
  • [Cites] World J Gastroenterol. 2008 Jan 28;14(4):632-5 [18203300.001]
  • [Cites] J Viral Hepat. 2008 Mar;15(3):179-87 [18233991.001]
  • [Cites] Int J Infect Dis. 2008 Nov;12(6):e71-6 [18658001.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2471-7 [10861422.001]
  • (PMID = 20143468.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2825336
  •  go-up   go-down


59. Liu XF, Zhou XT, Zou SQ: An analysis of 680 cases of cholangiocarcinoma from 8 hospitals. Hepatobiliary Pancreat Dis Int; 2005 Nov;4(4):585-8
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of 680 cases of cholangiocarcinoma from 8 hospitals.
  • BACKGROUND: The outcome of patients with cholangiocarcinoma is poor.
  • To evaluate the experience in the diagnosis and surgical treatment of cholangiocarcinoma, we investigated the status quo of diagnosis and treatment of cholangiocarcinoma in China.
  • METHOD: The clinical data of 680 patients with cholangiocarcinoma treated at 8 hospitals from 1995 to 2001 were retrospectively analyzed with SPSS software package.
  • Proximal cholangiocarcinoma was the commonest (41.6%) and distant cholangiocarcinoma the second (28.7%) in the 680 patients.
  • B-mode ultrasonography for cholangiocarcinoma was performed in 80.3% of the patients.
  • Most of the patients suffered from late-stage cholangiocarcinoma.
  • CONCLUSIONS: Cholangiocarcinoma is common in the aged men.
  • Most patients are diagnosed as having late-stage cholangiocarcinoma at the time of outpatient clinic, and the rate of radical operation is low.
  • Therefore, it is necessary to reinforce the early diagnosis and treatment of cholangiocarcinoma to improve the outcome after operation.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / pathology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. China / epidemiology. Humans. Incidence. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286268.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] China
  •  go-up   go-down


60. Shen WF, Zhong W, Xu F, Kan T, Geng L, Xie F, Sui CJ, Yang JM: Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. World J Gastroenterol; 2009 Dec 21;15(47):5976-82
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma.
  • AIM: To understand the clinicopathological characteristics and treatment selections and improve survival and provide valuable information for patients with intrahepatic cholangiocarcinoma (ICC).
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2005 Jun;29(6):728-33 [15880276.001]
  • [Cites] Am J Surg. 2005 Feb;189(2):173-7 [15720985.001]
  • [Cites] Chirurg. 2006 Jan;77(1):53-60 [16170505.001]
  • [Cites] Dig Dis Sci. 2006 Feb;51(2):338-45 [16534678.001]
  • [Cites] J Gastrointestin Liver Dis. 2006 Mar;15(1):9-14 [16680226.001]
  • [Cites] J Hepatol. 2006 Jul;45(1):43-50 [16690156.001]
  • [Cites] Liver Int. 2006 Aug;26(6):680-7 [16842324.001]
  • [Cites] J Hepatol. 2006 Dec;45(6):856-67 [17030071.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Nov;33(12):1834-7 [17212121.001]
  • [Cites] Ann Surg. 2007 May;245(5):755-62 [17457168.001]
  • [Cites] Am J Gastroenterol. 2007 May;102(5):1016-21 [17324130.001]
  • [Cites] Am J Surg. 2007 Jul;194(1):17-22 [17560903.001]
  • [Cites] World J Surg. 2007 Sep;31(9):1782-7 [17610113.001]
  • [Cites] World J Gastroenterol. 2008 Jan 28;14(4):632-5 [18203300.001]
  • [Cites] Surgery. 2008 Mar;143(3):366-74 [18291258.001]
  • [Cites] Int J Surg Pathol. 2008 Apr;16(2):194-8 [18417680.001]
  • [Cites] Am J Gastroenterol. 2008 Jul;103(7):1716-20 [18557716.001]
  • [Cites] Adv Ther. 2008 Oct;25(10):1075-84 [18821070.001]
  • [Cites] Transplant Proc. 2008 Nov;40(9):3194-5 [19010231.001]
  • [Cites] Br J Surg. 2000 Sep;87(9):1182-7 [10971425.001]
  • [Cites] Tumour Biol. 2001 Sep-Oct;22(5):318-22 [11553862.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):959-64 [11808716.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Hepatogastroenterology. 2002 Mar-Apr;49(44):311-6 [11995440.001]
  • [Cites] Gut. 2002 Nov;51 Suppl 6:VI1-9 [12376491.001]
  • [Cites] Br J Surg. 2002 Dec;89(12):1525-31 [12445060.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(4):259-64 [14598144.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(4):282-7 [14598146.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(6):432-40 [14714164.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):265-71 [14745336.001]
  • [Cites] World J Gastroenterol. 2004 Feb 1;10(3):427-32 [14760772.001]
  • [Cites] J Hepatol. 2004 Mar;40(3):472-7 [15123362.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1544-7 [15362797.001]
  • [Cites] Science. 1981 Apr 3;212(4490):53-5 [6163212.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):429-36 [9358085.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):117-21 [10398897.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):134-43 [15622001.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • (PMID = 20014463.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2795186
  • [Keywords] NOTNLM ; Diagnosis / Intrahepatic cholangiocarcinoma / Pathology / Surgery / Survival
  •  go-up   go-down


61. Zhang KJ, Zhang BY, Zhang KP, Tang LM, Liu SS, Zhu DM, Zhang DL: Clinicopathologic significance of slug expression in human intrahepatic cholangiocarcinoma. World J Gastroenterol; 2010 May 28;16(20):2554-7
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic significance of slug expression in human intrahepatic cholangiocarcinoma.
  • AIM: To explore the expression and function of slug, a transcriptional repressor, in human intrahepatic cholangiocarcinoma (IHCC) and identify its role in IHCC progression.
  • The patients were divided into low slug expression group (< 20% of carcinoma cells stained) and high slug expression group (> or = 20% of carcinoma cells stained).
  • [MeSH-major] Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic / metabolism. Cholangiocarcinoma / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Disease Progression. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Trends Genet. 2009 Jun;25(6):248-52 [19427053.001]
  • [Cites] J Cell Sci. 2003 Feb 1;116(Pt 3):499-511 [12508111.001]
  • [Cites] Cancer J. 2009 May-Jun;15(3):255-6 [19556913.001]
  • [Cites] Liver Int. 2010 Feb;30(2):215-21 [19840244.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1174-80 [15709186.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):155-65 [15790452.001]
  • [Cites] Oncogene. 2005 Apr 28;24(19):3073-82 [15735690.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):488-96 [15864483.001]
  • [Cites] Nat Genet. 2005 Oct;37(10):1047-54 [16142232.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8070-8 [16299238.001]
  • [Cites] Nihon Rinsho. 2006 Jan;64 Suppl 1:469-75 [16457307.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1816-22 [16773075.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4257-64 [16857800.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5395-402 [17000672.001]
  • [Cites] J Pathol. 2007 Apr;211(5):507-15 [17299729.001]
  • [Cites] Korean J Hepatol. 2007 Jun;13(2):125-8 [17585185.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2007 Aug;19(8):615-7 [17625428.001]
  • [Cites] Gut. 2007 Dec;56(12):1755-6 [17998326.001]
  • [Cites] World J Gastroenterol. 2008 Feb 21;14(7):1044-52 [18286686.001]
  • [Cites] J Am Coll Surg. 2008 Oct;207(4):594-603 [18926465.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):155-66 [11994736.001]
  • (PMID = 20503457.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Transcription Factors; 0 / snail family transcription factors
  • [Other-IDs] NLM/ PMC2877187
  •  go-up   go-down


62. Wakasa T, Wakasa K, Shutou T, Hai S, Kubo S, Hirohashi K, Umeshita K, Monden M: A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma. Hepatogastroenterology; 2007 Mar;54(74):508-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.
  • BACKGROUND/AIMS: Combined hepatocellular and cholangiocarcinoma of the liver is relatively infrequent, and its pathogenesis remains obscure.
  • METHODOLOGY: In this study, we investigated the histopathological features, Ki-67 labeling index, and p53 immunohistochemistry of 18 surgically resected cases of combined hepatocellular and cholangiocarcinoma among 1102 consecutive cases of surgically resected primary liver cancers.
  • Microscopically, we classified the cases into the following three categories according to the arrangement of the hepatocellular carcinoma and cholangiocarcinoma components;.
  • (1) Type I in which hepatocellular carcinoma and cholangiocarcinoma formed nodules that could easily be distinguished from each other, (2) Type II in which the both components were finely mixed, so that the two components were almost indistinguishable, and (3) Type III in which the tumors had lobular structures with hepatocellular carcinomas existing centrally and cholangiocarcinomas existing peripherally.
  • In one case of type I, well differentiated hepatocellular carcinoma demonstrated cholangiocarcinoma in "nodules-in-nodules" fashion.
  • The average of Ki-67 labeling index of hepatocellular carcinoma component of combined hepatocellular and cholangiocarcinoma was 4.4 +/- 3.4% and the index of cholangiocarcinoma component was 11.0 +/- 8.5%, which is significantly higher than that of the hepatocellular carcinoma component.
  • In one case, the cholangiocarcinoma component was positive for p53, but the hepatocellular carcinoma component was negative.
  • In the other 4 cases, both the hepatocellular carcinoma and cholangiocarcinoma components were positive.
  • Metaplasia of hepatocellular carcinoma to intrahepatic cholangiocarcinoma is assumed to be one of the pathogenic pathways of combined hepatocellular and cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Aged. Cell Division / physiology. Cell Transformation, Neoplastic / pathology. Female. Hepatitis B, Chronic / pathology. Hepatitis C, Chronic / pathology. Humans. Immunoenzyme Techniques. Ki-67 Antigen / analysis. Liver / pathology. Male. Metaplasia. Middle Aged. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523309.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


63. Kim JH, Kim TK, Eun HW, Byun JY, Lee MG, Ha HK, Auh YH: CT findings of cholangiocarcinoma associated with recurrent pyogenic cholangitis. AJR Am J Roentgenol; 2006 Dec;187(6):1571-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT findings of cholangiocarcinoma associated with recurrent pyogenic cholangitis.
  • OBJECTIVE: The purpose of our study was to determine the characteristic CT findings of cholangiocarcinoma associated with recurrent pyogenic cholangitis.
  • CONCLUSION: CT findings of cholangiocarcinoma associated with recurrent pyogenic cholangitis are important in order to improve early diagnosis and proper treatment.
  • Cholangiocarcinoma associated with recurrent pyogenic cholangitis is predominantly located in the atrophic hepatic lobes and in the hepatic lobes of biliary calculi and is associated with the narrowing or obliteration of the portal vein.
  • [MeSH-major] Bile Duct Neoplasms / radiography. Bile Ducts, Intrahepatic / radiography. Cholangiocarcinoma / radiography. Cholangitis / complications. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Recurrence

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114552.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Li Q, Wang JM, Liu C, Xiao BL, Lu JX, Zou SQ: Correlation of aPKC-iota and E-cadherin expression with invasion and prognosis of cholangiocarcinoma. Hepatobiliary Pancreat Dis Int; 2008 Feb;7(1):70-5
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of aPKC-iota and E-cadherin expression with invasion and prognosis of cholangiocarcinoma.
  • This study was designed to investigate the correlation of expression of aPKC-iota and E-cadherin with the clinicopathological characteristics and prognosis of cholangiocarcinoma, and to analyze the molecular mechanisms of invasion and metastasis of the tumor.
  • METHODS: EnVision immunohistochemistry was used to detect the expression of aPKC-iota and E-cadherin in 9 specimens of benign bile duct tissues, 35 specimens of cholangiocarcinoma and 6 specimens of metastatic cholangiocarcinoma.
  • The relationship of the expression with clinicopathological characteristics, invasion and prognosis of cholangiocarcinoma was analyzed.
  • RESULTS: The positive expression level of aPKC-iota in cholangiocarcinoma was remarkably higher than that in benign bile duct tissues (68.6% vs. 11.1%, P=0.006), but the expression level of E-cadherin was lower in cholangiocarcinoma than in benign bile duct tissues (37.1% vs. 88.9%, P=0.016).
  • Univariate analysis showed that the overall survival rate of the group with a higher expression of aPKC-iota in cholangiocarcinoma was remarkably lower than that of the group with a lower expression (P<0.01); multivariate analysis revealed that the expressions of aPKC-iota and E-cadherin are important prognostic factors for cholangiocarcinoma (P<0.05).
  • CONCLUSIONS: The expressions of aPKC-iota and E-cadherin may reflect the differentiation and invasive potential of cholangiocarcinoma. aPKC-iota and E-cadherin may be independent prognostic factors and, when used in combination with clinicopathological characteristics, may increase the accuracy in predicting the prognosis of patients with cholangiocarcinoma.
  • As a polar regulative associated protein, aPKC-iota may play an important role in the invasion and metastasis of cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic / metabolism. Cadherins / metabolism. Cholangiocarcinoma / metabolism. Isoenzymes / metabolism. Protein Kinase C / metabolism
  • [MeSH-minor] Adult. Aged. Cell Polarity. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Prognosis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18234642.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cadherins; 0 / Isoenzymes; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / protein kinase C lambda
  •  go-up   go-down


65. Ghali P, Marotta PJ, Yoshida EM, Bain VG, Marleau D, Peltekian K, Metrakos P, Deschênes M: Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl; 2005 Nov;11(11):1412-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience.
  • Cholangiocarcinoma is a biliary tumor, which not infrequently complicates primary sclerosing cholangitis.
  • The goal of this retrospective study was to perform a national review of outcomes after liver transplantation in Canadian recipients found to have incidental cholangiocarcinoma in their explanted native liver.
  • Six of the seven liver transplant centers in Canada provided clinical and follow-up information on all liver transplant recipients found to have incidental cholangiocarcinoma in their explants.
  • The diagnosis or suspicion of cholangiocarcinoma prior to transplantation were exclusion criteria for this study.
  • Ten individuals with cholangiocarcinoma were transplanted between 1996 and 2003.
  • In conclusion, although early survival of patients transplanted for incidental cholangiocarcinoma appears good, intermediate- and long-term survival rates are not better than for individuals historically transplanted with known cholangiocarcinoma.
  • Aggressive investigation for cholangiocarcinoma is mandated.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery. Incidental Findings. Liver Transplantation / methods
  • [MeSH-minor] Adult. Aged. Canada. Female. Follow-Up Studies. Graft Rejection. Graft Survival. Humans. Male. Middle Aged. Postoperative Complications / epidemiology. Probability. Retrospective Studies. Risk Assessment. Survival Analysis

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16237695.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Han F, Zhou JX, Zhang L, Han YZ: [Hepatectomy with portal vein resection and reconstruction in the treatment of hilar cholangiocarcinoma]. Zhonghua Wai Ke Za Zhi; 2007 Jun 1;45(11):763-5
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatectomy with portal vein resection and reconstruction in the treatment of hilar cholangiocarcinoma].
  • OBJECTIVE: To summarize the clinical experience and the role of hepatectomy with portal vein resection and reconstruction hilar cholangiocarcinoma.
  • METHODS: From 1998 to 2003, the clinical records of 118 cases with hilar cholangiocarcinoma were reviewed.
  • CONCLUSIONS: Portal vain invasion is not the contraindication of resection for hilar cholangiocarcinoma.
  • Hepatectomy with portal vein resection and reconstruction may raise the radical resection rate of hilar cholangiocarcinoma and improve the results of prognosis.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery. Hepatectomy / methods. Portal Vein / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Reconstructive Surgical Procedures. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17825201.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


67. Yang WL, Zhang XC, Zhang DW, Tong BF: Diagnosis and surgical treatment of hepatic hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int; 2007 Dec;6(6):631-5
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and surgical treatment of hepatic hilar cholangiocarcinoma.
  • BACKGROUND: Hepatic hilar cholangiocarcinoma can be diagnosed early with the progress in diagnostic imaging, and thus the rate of resection of the tumor has increased markedly.
  • To assess the effectiveness of resection, we reviewed 185 cases of hepatic hilar cholangiocarcinoma diagnosed and treated at our hospital.
  • METHODS: The clinical data of 185 patients with hepatic hilar cholangiocarcinoma who had been treated surgically from 1972 to 2006 were retrospectively analyzed.
  • Primary symptoms included upper abdominal discomfort or pain, anorexia, tiredness, weight loss and progressive jaundice.
  • CONCLUSIONS: Once patients are diagnosed with hepatic hilar cholangiocarcinoma, they should undergo exploratory laparotomy.
  • Resection is the most effective method for the treatment of hepatic hilar cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Cholangiopancreatography, Endoscopic Retrograde. Drainage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086631.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


68. Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM: Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst; 2006 Jun 21;98(12):873-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States.
  • Although hilar cholangiocarcinomas (Klatskin tumors) are extrahepatic cholangiocarcinomas, the second edition of the ICD-O (ICD-O-2) assigned them a histology code 8162/3, Klatskin, which was cross-referenced to intrahepatic cholangiocarcinoma.
  • Recent studies in the United States that included this code (8162/3, Klatskin) with intrahepatic cholangiocarcinoma reported an increasing incidence of intrahepatic cholangiocarcinoma and a decreasing incidence of extrahepatic cholangiocarcinoma.
  • To investigate the impact of this misclassification on site-specific cholangiocarcinoma incidence rates, we calculated annual percent changes (APCs) with data from the Surveillance, Epidemiology, and End Results (SEER) program using a Poisson regression model that was age-adjusted to the year 2000 U.S. population.
  • Ninety-one percent (246 of 269) of the hilar cholangiocarcinomas were incorrectly coded as intrahepatic cholangiocarcinomas, resulting in an overestimation of intrahepatic cholangiocarcinoma incidence by 13% and underestimation of extrahepatic cholangiocarcinomas incidence by 15%.
  • However, even after the exclusion of tumors that were coded to the histology code 8162/3, Klatskin, age-adjusted annual intrahepatic cholangiocarcinoma incidence increased during this period (APC = 4%, 95% confidence interval = 2% to 6%, P<.001).
  • [MeSH-major] Bile Duct Neoplasms / classification. Bile Duct Neoplasms / epidemiology. Bile Ducts, Extrahepatic. Bile Ducts, Intrahepatic. Cholangiocarcinoma / epidemiology. Klatskin Tumor / classification
  • [MeSH-minor] Adult. Aged. Female. Hepatic Duct, Common. Humans. Incidence. Male. Middle Aged. SEER Program. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2007 Mar 7;99(5):407; author reply 407-8 [17341733.001]
  • (PMID = 16788161.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


69. Zhou LX, Zhang ZW, Xu ZY: [An analysis on prognostic factors of hilar cholangiocarcinoma]. Zhonghua Yi Xue Za Zhi; 2009 May 12;89(18):1275-7
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An analysis on prognostic factors of hilar cholangiocarcinoma].
  • OBJECTIVE: To investigate the influencing factors on the prognosis of hilar cholangiocarcinoma.
  • METHODS: The clinical data were retrospectively analyzed in 86 cases of hilar cholangiocarcinoma admitted into our hospital from Jan.
  • RESULTS: Of 86 cases with hilar cholangiocarcinoma, the mean survival time was 13.7 +/- 2.3 months, 1-year survival 57.3% and 3-year survival 29.7%.
  • CONCLUSION: The prognosis of hilar cholangiocarcinoma correlates with operative approach, clinical stage and tumor diameter.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Cholangiocarcinoma / diagnosis
  • [MeSH-minor] Adult. Aged. Bile Ducts, Extrahepatic. Bile Ducts, Intrahepatic. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19595185.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


70. Sun Y, Wu ZY, Hao CY, Huang XF, Wang K, Bao Q, Qian HG, Xing BC: [Clinical analysis of curative resection with hemihepatectomy for advanced hilar cholangiocarcinoma]. Zhonghua Yi Xue Za Zhi; 2008 Feb 26;88(8):527-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of curative resection with hemihepatectomy for advanced hilar cholangiocarcinoma].
  • OBJECTIVE: To investigate the superiority of curative resection with hemihepatectomy in treatment of hilar cholangiocarcinoma and the strategy to lower the incidence of complications and mortality.
  • METHODS: The clinical data of 50 patients with hilar cholangiocarcinoma who underwent surgical procedures in Peking University School of Oncology from January 1998 to May 2006 were retrospectively analyzed.
  • CONCLUSION: Curative resection with hemihepatectomy is a safe and effective option for hilar cholangiocarcinoma, especially for Bismuth III or IV type.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery. Hepatectomy / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649767.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


71. Vij K, Wang HL: Aberrant expression of alpha-fetoprotein in intrahepatic cholangiocarcinoma: an exceptional occurrence. Int J Surg Pathol; 2008 Apr;16(2):194-8
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of alpha-fetoprotein in intrahepatic cholangiocarcinoma: an exceptional occurrence.
  • A high level of serum alpha-fetoprotein (AFP) is typically indicative of hepatocellular carcinoma in patients with liver lesions.
  • In this article, we describe an exceptional case of intrahepatic cholangiocarcinoma that occurred in a 36-year-old man with a markedly elevated serum AFP level (12310.7 ng/mL).
  • Histopathologic examination of surgically resected liver mass showed classic morphologic features of cholangiocarcinoma, with no hepatocellular carcinoma component identified.
  • To the best of our knowledge, this is the first documented case of AFP-producing intrahepatic cholangiocarcinoma with immunohistochemical evidence confirming the tumor cells to be the source of high-level AFP production.
  • [MeSH-major] Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic / metabolism. Cholangiocarcinoma / metabolism. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Humans. Male. Neoplasm Proteins / metabolism. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417680.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins
  •  go-up   go-down


72. Thelen A, Scholz A, Benckert C, Schröder M, Weichert W, Wiedenmann B, Neuhaus P, Jonas S: Microvessel density correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma. J Gastroenterol; 2008;43(12):959-66
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvessel density correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma.
  • However, little is known about the tumor-associated neovascularization in hilar cholangiocarcinoma.
  • The present study was conducted to analyze tumor-associated neovascularization in hilar cholangiocarcinoma and to determine its influence on tumor growth, metastasis, recurrence, and prognosis.
  • METHODS: We analyzed tissue specimens of hilar cholangiocarcinoma (n = 60) by immunohistochemistry using the endothelial-specific antibody CD31 and subsequently quantified the microvessel density (MVD).
  • RESULTS: Hilar cholangiocarcinoma revealed a high degree of vascularization, with a calculated mean MVD of 28.1 +/- 14.5 vessels.
  • CONCLUSIONS: Neovascularization is associated with nodal spread as well as local recurrence and serves as an independent prognostic factor for survival after curative resection of hilar cholangiocarcinoma.
  • In addition, neovascularization may represent a potential target in he development of new therapeutic approaches in hilar cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / physiopathology. Cholangiocarcinoma / physiopathology. Neovascularization, Pathologic / physiopathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD31 / immunology. Disease Progression. Disease-Free Survival. Female. Humans. Immunohistochemistry / methods. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / physiopathology. Male. Microvessels / pathology. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19107340.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD31
  •  go-up   go-down


73. Kim SJ, Lee JM, Han JK, Kim KH, Lee JY, Choi BI: Peripheral mass-forming cholangiocarcinoma in cirrhotic liver. AJR Am J Roentgenol; 2007 Dec;189(6):1428-34
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral mass-forming cholangiocarcinoma in cirrhotic liver.
  • OBJECTIVE: The purpose of this study was to determine whether particular enhancement patterns of intrahepatic cholangiocarcinoma in cirrhotic liver suggest the correct diagnosis.
  • MATERIALS AND METHODS: The CT findings on 28 lesions in 26 patients with underlying liver cirrhosis and pathologically proven cholangiocarcinoma were retrospectively evaluated.
  • The CT findings of hepatocellular carcinoma (HCC) in a control group of 79 subjects also were analyzed.
  • The difference between the enhancement pattern of cholangiocarcinoma and that of HCC was statistically analyzed with the Fisher's exact test.
  • RESULTS: The prevalent enhancement patterns of cholangiocarcinoma on enhanced CT scans differed depending on tumor size.
  • For tumors smaller than 3 cm in diameter, there was no significant difference between the enhancement pattern of cholangiocarcinoma and that of HCC.
  • For tumors larger than 3 cm, the presence of peripheral rimlike enhancement or centripetal enhancement and the absence of a washout pattern were significant findings for differentiating cholangiocarcinoma from HCC (p < 0.0001).
  • CONCLUSION: The contrast enhancement patterns of cholangiocarcinoma in cirrhotic liver on multiphasic helical CT scans were found to differ depending on tumor size.
  • Because of the overlapping imaging findings in the two diseases, for any hypovascular lesion smaller than 3 cm in a cirrhotic liver, the diagnosis of cholangiocarcinoma should be seriously considered along with that of HCC.
  • [MeSH-major] Bile Duct Neoplasms / radiography. Bile Ducts, Intrahepatic / radiography. Carcinoma, Hepatocellular / radiography. Cholangiocarcinoma / radiography. Liver Cirrhosis / radiography. Liver Neoplasms / radiography. Radiographic Image Enhancement / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18029881.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


74. Zhang BY, Lu Y, Dong Q, Sun CD, Mu P: Surgical treatment and prognostic analysis of 93 cases of hilar cholangiocarcinoma. Am J Med Sci; 2010 Mar;339(3):221-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment and prognostic analysis of 93 cases of hilar cholangiocarcinoma.
  • OBJECTIVE: To explore the surgical treatment and prognosis of hilar cholangiocarcinoma.
  • METHODS: This was a retrospective study of 93 cases of hilar cholangiocarcinoma that were treated surgically at our hospital from June 1999 to June 2005.
  • Patient age, serum total bilirubin, clinical type of Bismuth-Corlette, tumor differentiation, and lymph node metastases were important factors for predicting the prognosis of hilar cholangiocarcinoma.
  • CONCLUSIONS: Resection was the main treatment for hilar cholangiocarcinoma, and curative resection was the best way to obtain better prognosis.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / pathology. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate / trends. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20220331.001).
  • [ISSN] 1538-2990
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Liu XF, Kong FM, Xu Z, Yu SP, Sun FB, Zhang CS, Huang QX, Zhou XT, Song ZW: Promoter hypermethylation of death-associated protein kinase gene in cholangiocarcinoma. Hepatobiliary Pancreat Dis Int; 2007 Aug;6(4):407-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation of death-associated protein kinase gene in cholangiocarcinoma.
  • We studied the relationship of methylation status and expression of the DAPK gene with the clinical findings in cholangiocarcinoma.
  • RESULTS: Aberrant methylation of the DAPK gene was detected in 11 (30.6%) of 36 tissue specimens of cholangiocarcinoma, and in 2 (5.6%) of 36 specimens of adjacent normal tissues.
  • CONCLUSIONS: The frequency of DAPK gene methylation in cholangiocarcinoma is high and it may offer an effective means for earlier auxiliary diagnosis of the malignancy.
  • The DAPK gene epigenetically affected by methylation may be associated with the carcinogenesis of cholangiocarcinoma.
  • [MeSH-major] Apoptosis Regulatory Proteins / genetics. Apoptosis Regulatory Proteins / physiology. Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / genetics. Bile Ducts, Intrahepatic / pathology. Calcium-Calmodulin-Dependent Protein Kinases / genetics. Calcium-Calmodulin-Dependent Protein Kinases / physiology. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / genetics. DNA Methylation. Epigenesis, Genetic. Gene Expression Regulation, Neoplastic. Promoter Regions, Genetic
  • [MeSH-minor] Adult. Aged. Calmodulin / metabolism. Death-Associated Protein Kinases. Female. Humans. Male. Middle Aged. Sulfites / chemistry

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • Hazardous Substances Data Bank. SODIUM BISULFITE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690039.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Calmodulin; 0 / Sulfites; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; TZX5469Z6I / sodium bisulfite
  •  go-up   go-down


76. Li J, Liu B, Hou Y, Gao HB, Cai XP: [Surgical treatment of hilar cholangiocarcinoma:experience of 53 cases]. Zhonghua Wai Ke Za Zhi; 2009 Aug 1;47(15):1142-4
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of hilar cholangiocarcinoma:experience of 53 cases].
  • OBJECTIVE: To summarize the experience of surgical treatment of the hilar cholangiocarcinoma and explore the factors influencing the operative effect.
  • METHODS: Fifty-three cases of hilar cholangiocarcinoma performed operation from January 1998 to January 2008 were divided into two groups: Group I included cases treated from January 1998 to December 2002 (totally 22 cases); Group II included cases treated from January 2003 to January 2008 (totally 31 cases).
  • CONCLUSIONS: Early diagnosis and radical resection are important to improve the prognosis for patients with hilar cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Drainage. Female. Follow-Up Studies. Hepatectomy. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021903.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


77. Thelen A, Scholz A, Benckert C, Weichert W, Dietz E, Wiedenmann B, Neuhaus P, Jonas S: Tumor-associated lymphangiogenesis correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma. Ann Surg Oncol; 2008 Mar;15(3):791-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated lymphangiogenesis correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma.
  • Currently, nothing is known about the impact of lymphangiogenesis on progression and prognosis in hilar cholangiocarcinoma.
  • METHODS: We analyzed tissue specimens of normal liver and hilar cholangiocarcinoma (n = 60) by immunohistochemistry using the lymphendothelial-specific antibody D2-40 and subsequently quantified lymphatic microvessel density (LVD).
  • RESULTS: In contrast to the low abundance of lymphatic vessels in nontransformed liver tissue, we found an induction of lymphangiogenesis in hilar cholangiocarcinoma.
  • CONCLUSIONS: Lymphangiogenesis is associated with increased frequency of tumor cells in lymphatics and lymph nodes in hilar cholangiocarcinoma.
  • In addition, lymphangiogenesis may represent a potential target in the development of new therapeutic approaches in hilar cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / physiopathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / physiopathology. Lymphangiogenesis / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172731.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


78. Boberg KM, Jebsen P, Clausen OP, Foss A, Aabakken L, Schrumpf E: Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol; 2006 Oct;45(4):568-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis.
  • BACKGROUND/AIMS: Primary sclerosing cholangitis (PSC) is associated with a high risk of cholangiocarcinoma development.
  • RESULTS: Among patients with cytological low-grade (n=9; 15%) or high-grade dysplasia/adenocarcinoma (n=13; 21%), 8 (36%) proved to have cholangiocarcinoma and 7 (32%) to have high-grade dysplasia (i.e. cholangiocarcinoma in situ) in bile ducts from explanted livers.
  • CONCLUSIONS: Brush cytology from bile duct strictures in PSC patients can detect cholangiocarcinoma in situ.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Biopsy / methods. Cholangiocarcinoma / pathology. Cholangitis, Sclerosing / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Adult. Aged. Biomarkers, Tumor. Carcinoma in Situ / pathology. Cholangiopancreatography, Endoscopic Retrograde. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Hepatol. 2006 Oct;45(4):476-9 [16901574.001]
  • (PMID = 16879890.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


79. Yi B, Zhang BH, Zhang YJ, Jiang XQ, Zhang BH, Yu WL, Cheng QB, Wu MC: [Analysis of the relation between surgery and prognosis of hilar cholangiocarcinoma]. Zhonghua Wai Ke Za Zhi; 2005 Jul 1;43(13):842-5
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the relation between surgery and prognosis of hilar cholangiocarcinoma].
  • OBJECTIVE: To explore the prognosis factors of hilar cholangiocarcinoma, and investigate the relation between operative procedure and prognosis of it.
  • METHODS: A retrospective cohort study was investigated in 198 patients with hilar cholangiocarcinoma, who were treated in our hospital from December 1997 to December 2002.
  • CONCLUSIONS: Operative procedure was the most important prognosic factor of hilar cholangiocarcinoma, radical resection still was the primary measure to cure and long term survival.
  • For irresectable hilar cholangiocarcinoma, the effect of ERBD or EMBE could not be considered to be worse than that of open operative treatment.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Biliary Tract Surgical Procedures / methods. Cholangiocarcinoma / surgery. Drainage / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083598.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


80. Kim BH, Cho NY, Choi M, Lee S, Jang JJ, Kang GH: Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas. Arch Pathol Lab Med; 2007 Jun;131(6):923-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas.
  • Extrahepatic cholangiocarcinoma has been poorly investigated with respect to CpG island hypermethylation, and the number of genes known to be methylated in extrahepatic cholangiocarcinomas is fewer than 20.
  • CDH1 and NEUROG1 were more frequently methylated in extrahepatic cholangiocarcinoma than in intrahepatic cholangiocarcinoma, whereas CHFR, GSTP1, IGF2, MGMT, MINT31, p14, and RBP1 were more frequently methylated in intrahepatic cholangiocarcinoma: the differences was statistically significant (P < .05).
  • [MeSH-major] Bile Duct Neoplasms / genetics. Bile Ducts, Extrahepatic. Bile Ducts, Intrahepatic. Cholangiocarcinoma / genetics. CpG Islands / genetics. DNA Methylation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Neoplasm / analysis. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Sequence Analysis, DNA


81. Kaiser GM, Frühauf NR, Lang H, Sauerwein W, Sotiropoulos GC, Zöpf T, Grabellus F, Wittig A, Oldhafer KJ, Malagó M, Broelsch CE: Impact of intraoperative radiotherapy (IORT) on survival of patients with unresectable hilar cholangiocarcinoma. Hepatogastroenterology; 2008 Nov-Dec;55(88):1951-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of intraoperative radiotherapy (IORT) on survival of patients with unresectable hilar cholangiocarcinoma.
  • BACKGROUND/AIMS: The cure or long-term survival of hilar cholangiocarcinoma patients can only be achieved after complete tumor resection.
  • Many patients though suffer from unresectable hilar cholangiocarcinoma, and palliative treatment is therefore the only therapeutic option.
  • The aim of this study was to compare the efficacy of IORT to surgery alone in patients with unresectable hilar cholangiocarcinoma.
  • METHODOLOGY: Palliative IORT (group 1) was performed on 9 patients (4 female/5 male); surgery alone (group 2) was performed in a case-matched group of 9 patients (4 female, 5 male) with unresectable hilar cholangiocarcinoma.
  • Group 1 was also compared to all 36 patients (n=36) suffering from unresectable cholangiocarcinoma treated without IORT (Group 3).
  • CONCLUSIONS: Palliative surgery including IORT is safe for patients with unresectable hilar cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Ducts, Intrahepatic. Cholangiocarcinoma / mortality. Cholangiocarcinoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Intraoperative Period. Liver Neoplasms / secondary. Male. Middle Aged. Palliative Care. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260456.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


82. Cai SW, Duan WD, Liu Z, Zhao XQ, Zhang WZ, Wang J, Huang XQ, Dong JH, Huang ZQ: [Experience from surgical resection for 48 cases of hilar cholangiocarcinoma]. Zhonghua Wai Ke Za Zhi; 2009 Aug 1;47(15):1138-41
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experience from surgical resection for 48 cases of hilar cholangiocarcinoma].
  • OBJECTIVE: To summarize the methods, safety and efficiency of surgical resection for hilar cholangiocarcinoma.
  • METHODS: The clinical and follow-up data of 48 patients with hilar cholangiocarcinoma underwent surgical resection from January 2003 to December 2007 were analyzed retrospectively.
  • CONCLUSIONS: Extended hepatic resection for hilar cholangiocarcinoma offers good outcomes with an acceptable mortality rate.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery. Hepatectomy / methods
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021902.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


83. Uhm KO, Lee ES, Lee YM, Kim HS, Park YN, Park SH: Aberrant promoter CpG islands methylation of tumor suppressor genes in cholangiocarcinoma. Oncol Res; 2008;17(4):151-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant promoter CpG islands methylation of tumor suppressor genes in cholangiocarcinoma.
  • To ascertain the mechanism of gene promoter hypermethylation in cholangiocarcinoma (CC), we investigated promoter methylation status of the candidate genes ID4, DLC-1, and SFRP1 in 41 CCs, 19 adjacent nontumor tissues, and 15 normal liver tissues using methylation-specific PCR (MSP).
  • Taken together, these results suggest that aberrant DNA methylation may contribute to the tumorigenesis of cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / genetics. Bile Ducts, Intrahepatic. Cholangiocarcinoma / genetics. CpG Islands. DNA Methylation. Genes, Tumor Suppressor. Promoter Regions, Genetic
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Epigenesis, Genetic. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773859.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


84. Boonsakan P, Thangnapakorn O, Tapaneeyakorn J, Kositchaiwat S, Bunyaratvej S: Case report combined hepatocellular and cholangiocarcinoma with sarcomatous transformation. J Med Assoc Thai; 2007 Mar;90(3):574-80
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report combined hepatocellular and cholangiocarcinoma with sarcomatous transformation.
  • Combined hepatocellular and cholangiocarcinoma with sarcomatous transformation was first recognized in Ramathibodi Hospital in 2005.
  • This variant of carcinoma has been increasingly reported particularly from Asian countries.
  • It is suggested that the recent change of the Thai peoples' life style to an increased consumption of fast foods containing food preservatives especially nitrate or nitrite, the nitrosamine precursor may allow heavy exposure(s) to the chemical carcinogen(s) i.e. nitrosamine(s) leading to sarcomatous transformation of the carcinoma.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Humans. Male. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427538.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


85. Sakata J, Shirai Y, Wakai T, Nomura T, Sakata E, Hatakeyama K: Catheter tract implantation metastases associated with percutaneous biliary drainage for extrahepatic cholangiocarcinoma. World J Gastroenterol; 2005 Nov 28;11(44):7024-7
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Catheter tract implantation metastases associated with percutaneous biliary drainage for extrahepatic cholangiocarcinoma.
  • AIM: To estimate the incidence of catheter tract implantation metastasis among patients undergoing percutaneous transhepatic biliary drainage (PTBD) for extrahepatic cholangiocarcinoma, and to provide data regarding the management of this unusual complication of PTBD by reviewing cases reported in the literature.
  • METHODS: A retrospective analysis of 67 consecutive patients who underwent PTBD before the resection of extrahepatic cholangiocarcinoma was conducted.
  • Among the 10 reported patients with catheter tract implantation metastasis from extrahepatic cholangiocarcinoma (including our three patients), two survived for more than 5 years after the excision of isolated catheter tract metastases.
  • CONCLUSION: Catheter tract implantation metastasis is not a rare complication following PTBD for extrahepatic cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic. Biliary Tract Surgical Procedures. Catheters, Indwelling. Cholangiocarcinoma
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drainage. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Seeding. Retrospective Studies. Review Literature as Topic. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437610.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4717048
  •  go-up   go-down


86. Cho ES, Park MS, Yu JS, Kim MJ, Kim KW: Biliary ductal involvement of hilar cholangiocarcinoma: multidetector computed tomography versus magnetic resonance cholangiography. J Comput Assist Tomogr; 2007 Jan-Feb;31(1):72-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biliary ductal involvement of hilar cholangiocarcinoma: multidetector computed tomography versus magnetic resonance cholangiography.
  • OBJECTIVE: To compare the diagnostic accuracy of multidetector computed tomography (MDCT) and magnetic resonance cholangiography (MRC) in evaluating the extent of biliary involvement of hilar cholangiocarcinoma.
  • METHODS: Images of 16-detector MDCT, MRC, and direct cholangiography of 33 patients with pathologically proven hilar cholangiocarcinoma were retrospectively interpreted independently by 2 radiologists according to the Bismuth classification.
  • CONCLUSIONS: In evaluating the biliary ductal extension of hilar cholangiocarcinoma, MDCT and MRC showed similar accuracies and agreements.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Cholangiocarcinoma / diagnosis. Cholangiography / methods. Magnetic Resonance Imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Reproducibility of Results. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17259836.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Leelawat K, Wannaprasert J: Cholangiocarcinoma in a 24-year-old woman with hepatolithiasis. J Med Assoc Thai; 2009 Jul;92(7):983-6
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholangiocarcinoma in a 24-year-old woman with hepatolithiasis.
  • Hepatolithiasis is well known to represent an etiology of cholangiocarcinoma.
  • The average age of patients with a diagnosis of cholangiocarcinoma that occurs as a complication of hepatolithiasis is about 62-year-old.
  • Here, the authors present a case of cholangiocarcinoma that occurred in a 24-year-old woman who presented with the recurrent cholangitis from hepatolithiasis.
  • Histopathological examination revealed that it was cholangiocarcinoma located in the inflammatory left hepatic duct.
  • [MeSH-major] Bile Duct Neoplasms / complications. Bile Ducts, Intrahepatic. Cholangiocarcinoma / complications. Lithiasis / complications. Liver Diseases / complications
  • [MeSH-minor] Adult. Female. Hepatectomy. Humans

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19626820.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


88. Thomas H, Heaton ND: Late recurrence after surgery for cholangiocarcinoma: implications for follow-up? Hepatobiliary Pancreat Dis Int; 2008 Oct;7(5):544-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrence after surgery for cholangiocarcinoma: implications for follow-up?
  • METHODS: We report a patient who developed recurrence 8 years after resection of cholangiocarcinoma.
  • Descriptions of late recurrence after excision of cholangiocarcinoma are reviewed.
  • There is a need to differentiate a new primary and field change from recurrence of the previous tumor.
  • CONCLUSIONS: Long-term follow-up after resection of cholangiocarcinoma is needed because late recurrence after 5 years occurs.
  • The mortality rate between 5 and 10 years after resection of cholangiocarcinoma ranges from 6% to 43% in different series.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Biliary Tract Surgical Procedures. Bone Neoplasms / secondary. Cholangiocarcinoma / surgery. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Differentiation. Chemotherapy, Adjuvant. Fatal Outcome. Humans. Male. Neoplasm Invasiveness. Palliative Care. Radiotherapy, Adjuvant. Time Factors

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18842505.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


89. Yin LL, Song B, Li YC, Chen X, Li CX, Zhong KX, Sun JY, Li ZL: [The value of MRI 3D-VIBE systems applied to preoperative estimate of hepatic portal cholangiocarcinoma]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Nov;37(6):928-33
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The value of MRI 3D-VIBE systems applied to preoperative estimate of hepatic portal cholangiocarcinoma].
  • OBJECTIVE: To explore the diagnostic value of the system serial of three-dimensional spoiled gradient-echo T1-weighted MR imaging (three-dimensional volumetric interpolated breath-hold examination, 3D-VIBE) used to the preoperative assessment of hepatic portal cholangiocarcinoma.
  • METHODS: 31 surgically confirmed patients with hepatic portal cholangiocarcinoma underwent the preoperative examination through MR imaging system serial that was including T2W, two dimension (2D) T1W plain scan, 2D magnetic resonance cholangiopancreatography (MRCP), and Gadolinium-enhanced 3D-VIBE triple-phase dynamic acquisitions followed by 2D T1W scanning at the equilibrium phase.
  • (1) (3D-VIBE directly displayed the hepatic portal tumors and correctly classified the tumor morphological types in all patients, but 2D T1W systems missed to show 8 hepatic portal cholangiocarcinoma of periductal-infiltrating type (25. 8%);.
  • CONCLUSION: 3D-VIBE system is superior to other MR imaging system serial in the preoperative assessment of the morphological type, the longitudinal infiltration extent and the tumor resectability of hepatic portal cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / diagnosis. Imaging, Three-Dimensional / methods. Magnetic Resonance Imaging / methods. Preoperative Period. Respiration
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236597.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


90. Lim MK, Ju YH, Franceschi S, Oh JK, Kong HJ, Hwang SS, Park SK, Cho SI, Sohn WM, Kim DI, Yoo KY, Hong ST, Shin HR: Clonorchis sinensis infection and increasing risk of cholangiocarcinoma in the Republic of Korea. Am J Trop Med Hyg; 2006 Jul;75(1):93-6
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonorchis sinensis infection and increasing risk of cholangiocarcinoma in the Republic of Korea.
  • To evaluate the prevalence and risk factors of Clonorchis sinensis infection, an epidemiologic survey was performed (3,169 residents; age range: 30-87 years; mean age = 59; 1,973 women) in three areas with different mortality rates of cholangiocarcinoma. C. sinensis prevalence was 2.1% in Chuncheon, 7.8% in Chungju, and 31.3% in Haman, where cholangiocarcinoma incidence rate was 0.3, 1.8, and 5.5 per 100,000 persons, respectively.
  • [MeSH-major] Bile Duct Neoplasms / epidemiology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / epidemiology. Clonorchiasis / epidemiology. Clonorchis sinensis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alcohol Drinking. Animals. Feces / parasitology. Female. Fishes. Geography. Humans. Korea / epidemiology. Male. Middle Aged. Risk Factors. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16837714.001).
  • [ISSN] 0002-9637
  • [Journal-full-title] The American journal of tropical medicine and hygiene
  • [ISO-abbreviation] Am. J. Trop. Med. Hyg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. Han SL, Zhou HZ, Cheng J, Lan SH, Zhang PC, Chen ZJ, Zeng QQ: Diagnosis and surgical treatment of intrahepatic hepatolithiasis associated cholangiocarcinoma. Asian J Surg; 2009 Jan;32(1):1-6
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and surgical treatment of intrahepatic hepatolithiasis associated cholangiocarcinoma.
  • The present report summarises the results and our experience for management of 23 patients with intrahepatic hepatolithiasis associated cholangiocarcinoma (IHHCC).
  • Hepatic resection with postoperative treatment is the treatment of choice for cholangiocarcinoma when it is resectable.

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19321395.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


92. Nishio H, Nagino M, Oda K, Ebata T, Arai T, Nimura Y: TNM classification for perihilar cholangiocarcinoma: comparison between 5th and 6th editions of the AJCC/UICC staging system. Langenbecks Arch Surg; 2005 Aug;390(4):319-27
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNM classification for perihilar cholangiocarcinoma: comparison between 5th and 6th editions of the AJCC/UICC staging system.
  • BACKGROUND: A few investigators have evaluated the TNM classification for perihilar cholangiocarcinoma.
  • METHODS: For 166 patients with perihilar cholangiocarcinoma undergoing R0 resection, survival curves stratified according to TNM classifications were compared between fifth and sixth editions.
  • CONCLUSIONS: The sixth edition provided improved prediction of survival in patients with perihilar cholangiocarcinoma; for still better prediction, cancer invasion of the portal bifurcation and regional lymph node metastasis should be weighted equally.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001285.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


93. Kobayashi A, Miwa S, Nakata T, Miyagawa S: Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma. Br J Surg; 2010 Jan;97(1):56-64
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma.
  • BACKGROUND: There is little information regarding the clinical behaviour of hilar cholangiocarcinoma after curative resection.
  • METHODS: A retrospective study was undertaken of 79 consecutive patients with hilar cholangiocarcinoma who had undergone major hepatectomy (three or more Couinaud segments) concomitant with caudate lobectomy, and had negative resection margins.
  • CONCLUSION: Distant metastases are more common than locoregional recurrence after R0 resection for hilar cholangiocarcinoma, and associated with nodal involvement and high T stage.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery. Hepatectomy / methods. Neoplasm Recurrence, Local / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 19937985.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


94. Abdel Wahab M, Mostafa M, Salah T, Fouud A, Kandeel T, Elshobary M, Abd Allah OF, Elghawalby N, Sultan A, Ezzat F: Epidemiology of hilar cholangiocarcinoma in Egypt: single center study. Hepatogastroenterology; 2007 Sep;54(78):1626-31
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of hilar cholangiocarcinoma in Egypt: single center study.
  • BACKGROUND/AIMS: Cholangiocarcinoma is the second most frequent malignant tumor of the liver after hepatocellular carcinoma.
  • The incidence rates of hilar cholangiocarcinoma (CC) vary greatly among different areas of the world, this variation is related to distribution of risk factors.
  • METHODOLOGY: This study included 440 patients with hilar cholangiocarcinoma who were admitted to the Gastrointestinal Surgical Center, Mansoura University between January 1995 and October 2004.
  • Liver cirrhosis, HCV, bilharziasis, chronic typhoid infection and gallstones can be possible risk factors for hilar cholangiocarcinoma in Egypt.
  • [MeSH-major] Bile Duct Neoplasms / epidemiology. Cholangiocarcinoma / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Egypt. Female. Gallstones / complications. Hepatitis C / complications. Humans. Liver Cirrhosis / complications. Male. Middle Aged. Residence Characteristics. Rural Population. Schistosomiasis / complications. Sex Factors. Typhoid Fever / complications

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019680.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


95. Kim YH, Kang KJ, Kwon JH: [Four cases of hepatic fascioliasis mimicking cholangiocarcinoma]. Korean J Hepatol; 2005 Jun;11(2):169-75
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Four cases of hepatic fascioliasis mimicking cholangiocarcinoma].
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Cholangiocarcinoma / diagnosis. Fascioliasis / diagnosis. Liver Diseases, Parasitic / diagnosis
  • [MeSH-minor] Adult. Diagnostic Errors. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Fascioliasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15980676.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


96. Kuo CM, Changchien CS, Wu KL, Chuah SK, Chiu KW, Chiu YC, Chou YP, Kuo CH: Mucin-producing cholangiocarcinoma: clinical experience of 24 cases in 16 years. Scand J Gastroenterol; 2005 Apr;40(4):455-9
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin-producing cholangiocarcinoma: clinical experience of 24 cases in 16 years.
  • OBJECTIVE: Mucin-producing cholangiocarcinoma (MPCC) is an uncommon biliary tract malignancy.
  • MATERIAL AND METHODS: The study included 24 MPCC cases (7 M, 17 F) from 132 histopathology-proven cholangiocarcinoma patients seen between 1988 and 2003.
  • MPCC and non-mucin-producing cholangiocarcinoma (non-MPCC) were compared.
  • In detecting MPCC, a serum CA-19-9 level > 120 U/ml had 73% sensitivity, 41% specificity, 25% positive predictive value, 85% negative predictive value, and 48% accuracy in the 132 cholangiocarcinoma patients.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. CA-19-9 Antigen / blood. Cholangiocarcinoma / diagnosis. Mucins / physiology
  • [MeSH-minor] Adult. Aged. Biliary Tract Surgical Procedures. Biomarkers, Tumor / blood. Cholelithiasis / complications. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028441.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Mucins
  •  go-up   go-down


97. Peycru T, Hardwigsen J, Grégoire E, Barbier L, Richa H, Campan P, Le Treut YP: [Radical surgery in intrahepatic cholangiocarcinoma]. Gastroenterol Clin Biol; 2009 Mar;33(3):187-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radical surgery in intrahepatic cholangiocarcinoma].
  • The aim of this retrospective study was to evaluate the results of surgical treatment of intrahepatic cholangiocarcinoma treated by the same team.
  • Between 1988 and 2005, 75 patients underwent surgery for intrahepatic cholangiocarcinoma.
  • In conclusion, intrahepatic cholangiocarcinoma is a tumor that often requires a major or an extended hepatectomy.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19237255.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


98. Chen RF, Li ZH, Zhou JJ, Wang J, Chen JS, Lin Q, Tang QB, Peng NF, Jiang ZP, Zhou QB: Preoperative evaluation with T-staging system for hilar cholangiocarcinoma. World J Gastroenterol; 2007 Nov 21;13(43):5754-9
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative evaluation with T-staging system for hilar cholangiocarcinoma.
  • AIM: To investigate the clinical value of T-staging system in the preoperative assessment of hilar cholangiocarcinoma.
  • METHODS: From March 1993 to January 2006, 85 patients who had cholangiocarcinoma diagnosed by operative tissue-biopsy were placed into one of three stages based on the new T-staging system, and it was evaluated the resectability and survival correlated with T-staging.
  • CONCLUSION: The proposed staging system for hilar cholangiocarcinoma can accurately predict resectability, the likelihood of metastatic disease, and survival.
  • MRCP/MRA coupled with color Doppler Ultrasonagraphy was necessary for preoperative evaluation of hilar cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / pathology. Neoplasm Staging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Cholangiopancreatography, Magnetic Resonance. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Preoperative Care / methods. Ultrasonography, Doppler, Duplex

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17963304.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4171264
  •  go-up   go-down


99. Sasaki R, Takeda Y, Funato O, Nitta H, Kawamura H, Uesugi N, Sugai T, Wakabayashi G, Ohkohchi N: Significance of ductal margin status in patients undergoing surgical resection for extrahepatic cholangiocarcinoma. World J Surg; 2007 Sep;31(9):1788-96
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of ductal margin status in patients undergoing surgical resection for extrahepatic cholangiocarcinoma.
  • OBJECTIVES: The objective of this study was to determine whether carcinoma in situ at the bile duct margin is prognostically different from residual invasive carcinoma in patients with extrahepatic cholangiocarcinoma.
  • Although there are many reports that the ductal margin status at bile duct resection stumps is a prognostic indicator in patients with extrahepatic cholangiocarcinoma, some patients who undergo resection with microscopic tumor involvement of the bile duct margin survive longer than expected.
  • METHODS: A retrospective clinicopathological analysis of 128 patients who had undergone surgical resection for extrahepatic cholangiocarcinoma was conducted.
  • The status of the bile duct resection margin was classified as negative in 105 patients (82.0%), positive for carcinoma in situ in 12 patients (9.4%), and positive for invasive carcinoma in 11 patients (8.6%).
  • There was no significant difference between patients with a negative ductal margin and those with a positive ductal margin with carcinoma in situ (p = 0.5247).
  • The 5-year survival rate of patients with a positive ductal margin with carcinoma in situ (22.2%) was significantly better (p = 0.0241) than with invasive carcinoma (0%).
  • CONCLUSIONS: Among patients undergoing surgical resection for extrahepatic cholangiocarcinoma, invasive carcinoma at the ductal resection margins appears to have a significant relation to local recurrence and also a significant negative impact on survival, whereas residual carcinoma in situ does not.
  • Discrimination whether carcinoma in situ or invasive carcinoma is present is important in clinical setting in which the resection margin at the ductal stump is positive.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic / pathology. Bile Ducts, Extrahepatic / surgery. Biliary Tract Surgical Procedures / methods. Carcinoma in Situ / surgery. Cholangiocarcinoma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17647056.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Uenishi T, Yamazaki O, Yamamoto T, Hirohashi K, Tanaka H, Tanaka S, Hai S, Kubo S: Serosal invasion in TNM staging of mass-forming intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg; 2005;12(6):479-83
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serosal invasion in TNM staging of mass-forming intrahepatic cholangiocarcinoma.
  • BACKGROUND/PURPOSE: The Liver Cancer Study Group of Japan established a tumor-nodule-metastasis (TNM) staging system for mass-forming intrahepatic cholangiocarcinoma, with T determined by tumor number and size and vascular or serosal invasion.
  • METHODS: Sixty-three patients who underwent hepatic resection for mass-forming intrahepatic cholangiocarcinoma were investigated retrospectively, with the investigation including univariate and multivariate analyses of potential prognostic factors.
  • CONCLUSIONS: Serosal invasion showed no survival impact after hepatic resection for mass-forming intrahepatic cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16365823.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement